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Impact of Chronic Conditions on Treatment, Cancer-and Non-Cancer Outcomes among Elderly 
Men with Incident Prostate Cancer  
Amitkumar Dineshchandra Raval 
 
Prostate Cancer is the most commonly observed non-skin cancer among the elderly men aged 65 
years and older in the United States.  Nearly one third of elderly men diagnosed with incident prostate 
cancer have pre-existing chronic conditions. Therefore, among elderly men with prostate cancer, 
management for cancer and chronic conditions should be optimized to improve healthcare outcomes. 
Previous literature majorly focused on the risk and management of cancer in the presence of number 
of conditions, although, it is known that more than 70% of chronic conditions among men diagnosed 
with prostate cancer were either cardio-metabolic, respiratory or mental health conditions. Lack of 
evidence persists regarding the impact of common types of chronic conditions and their conditions 
among elderly men with prostate cancer and vice-versa. The current study is an attempt to shrink the 
knowledge gap to provide actionable strategies to better management of chronic conditions and 
prostate cancer among elderly men. The three specific aims of the study were to: (1) examine the 
associations between the types of pre-existing chronic conditions and cancer stage at diagnosis, initial 
cancer treatment and clinical outcomes after initial cancer treatment; 2) examine the relationship 
between metformin use and cancer stage at diagnosis, and the initial cancer-treatment; 3) analyze the 
impact of cancer diagnosis on the risk of non-cancer hospitalizations and evaluate whether the impact 
of cancer diagnosis on the risk of non-cancer hospitalizations vary by the types of pre-existing chronic 
conditions among fee-for-service elderly Medicare beneficiaries with incident prostate cancer. The 
study used a retrospective cohort design, using multiple years (2002-2010) of the cancer registry data 
from the Surveillance, Epidemiology and End Results (SEER) program linked with the Medicare 
administrative claims data and the Area Health Resource Files (AHRF).  In the first aim, among 
elderly men with incident prostate cancer (N = 103,820), the cardio-vascular conditions were the most 
common chronic condition. 1 in 10 elderly men had advanced prostate cancer at diagnosis. Elderly 
men without cardio-metabolic, respiratory or mental health conditions were more likely to be 
diagnosed with advanced prostate cancer as compared to those with all the three types of chronic 
conditions. 3 in 4 elderly men with localized prostate cancer received either radical prostatectomy 
(RP), radiation therapy (RT) or hormone therapy during the first six-month after cancer diagnosis. As 
compared to all three types of chronic conditions, those with single types of chronic conditions were 
less likely to develop bowel, and urinary dysfunctions. In the second aim, the use of metformin was 
associated with a reduction in the risk of advanced prostate cancer among elderly men diagnosed with 
prostate cancer and pre-existing diabetes (N=2, 652). In the third study, elderly men diagnosed with 
prostate cancer had an increase in the risk of non-cancer hospitalizations during the post-cancer period 
as compared to the pre-cancer period in both unadjusted and adjusted analyses.  The highest rates of 
non-cancer hospitalizations were observed during first four months after the diagnosis of prostate 
cancer.  To summarize, our study confirms that elderly men with incident prostate cancer and multiple 
types of pre-existing chronic conditions would pose a different degree of risk for the development of 
advanced prostate cancer. Although the management of chronic conditions such diabetes with 
metformin may reduce the risk of advanced prostate cancer among elderly men. An overuse of RT/RP 
in men with different types of chronic conditions and an increase in the non-cancer hospitalizations in 
the initial period after diagnosis of prostate cancer suggest the scope of optimum use of RT and RP 
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 Many elderly men (age > 65 years) in the United States (US) have pre-existing chronic 
conditions when diagnosed with cancer. The presence of pre-existing chronic conditions is associated 
with poor quality of life and cancer-related outcomes. But limited evidence exists on how particular 
types of chronic conditions affect the risk of aggressive cancer, cancer treatment and clinical 
outcomes among elderly men with cancer.  The management of some of the pre-existing chronic 
conditions may have beneficial effects on cancer care. For example, the management of pre-existing 
diabetes with metformin may not only improve the outcomes of diabetes, but also reduce the risk of 
cancer incidence or prevent aggressive cancers.  Conversely, the diagnosis of cancer can be eclipse 
the management of pre-existing chronic conditions and affect non-cancer outcomes such as 
hospitalizations not related to the cancer.  To date, no population-based study has addressed this issue 
among elderly men with cancer.  
Therefore, the overall goal of the dissertation is to analyze the influence of pre-existing 
chronic conditions on cancer stage, cancer treatment, cancer-related clinical outcomes, and non-cancer 
outcomes (example: hospitalizations), and analyze the impact of pharmacological agents (example: 
metformin) used to manage pre-existing conditions (example: diabetes) on the cancer stage and the 
treatment for cancer. For the purposes of this dissertation, elderly men with prostate cancer was 
selected because of it is the leading cancer in men accounting for one fourth of all cancer cases 
diagnosed in the US. 
The dissertation is organized as follows:  Chapter 1 briefly describes the epidemiology of 
prostate cancer in the US, the prevalence of pre-existing chronic conditions among men with prostate 
cancer, the need for the study, conceptual framework for the study, and data sources for the study. 
Chapter 2 focuses on the association between the types of chronic conditions and stage of diagnosis, 
the treatment for prostate cancer and clinical outcomes.  Chapter 3 emphases on the relationship 
management of pre-existing condition, specifically type 2 diabetes mellitus (T2DM) on the stage of 




mellitus (T2DM) with metformin, as the first-line treatment for diabetes on the stage of cancer and the 
cancer treatment is analyzed.  The chapter 4 highlights the relationship between pre-existing chronic 
conditions and non-cancer hospitalizations.  Chapter 5 summarizes the study findings from the 
chapters 2, 3, and 4, and includes a discussion of the findings, implications and recommendations for 
future research. The advantages and limitations of the study findings are also included.   
1.1.2 Epidemiology of Prostate Cancer in the US 
Prostate cancer is a cancer of a gland surrounding the neck of the urinary bladder in men.  It is 
the most common non-cutaneous (non-skin) cancer among men in the US. As of 2015, nearly 2.9 
million prostate cancer survivors are alive, and about 222,800 new cases of prostate cancer are 
expected in 2015. Prostate cancer accounts for 24% of all cancer cases (1).  Nearly two thirds of 
prostate cancer cases are diagnosed among the elderly men aged 65 years and older (2).  
1.1.3 Cancer Stage at Diagnosis 
Prostate cancer is often diagnosed at an earlier stage. The American Joint Committee on 
Cancer (AJCC) defines the stage of Prostate cancer by the Tumor, Nodes, and Metastasis (TNM) 
Staging System.  The TNM system classifies a stage based on the spread of tumors to the local area, 
node, or metastases to other organs. “T” denotes for the extent of tumors in the prostate gland, “N” 
denotes spread of cancer to lymph nodes and “M” indicates the absence or presence of distant 
metastasis to bone, lung, liver or brain.  Early stage tumors are confined to the prostate gland with no 
spread of cancer to the seminal vesicles or the lymph nodes or metastases (T1-T2, N0, M0). These 
types of cancers are also termed as localized or organ-confined cancer.  Four in every five incident 
prostate cases (80%) are diagnosed at the localized stage of prostate cancer.  
Locally advanced prostate cancer, i.e. aggressive types of prostate cancer usually spreads to 
nearby regions of the prostate, including seminal vesicles, pelvic nodes, neck of the bladder or back 
passage or metastasis in bone or other organs (T3-T4, N1, M1). Less than one in every five incident 
prostate cancer cases are diagnosed as advanced prostate cancer.  Details of the TNM staging for the 




1.1.4 Prostate Cancer Treatment 
Treatment options for prostate cancer vary depending on age, cancer stage, and the presence 
of serious chronic conditions. Traditional treatment modalities for prostate cancer include surgery to 
remove the tumors (radical prostatectomy - RP), radiation therapy (RT), and hormone therapy. The 
use of aggressive therapies such as RP or RT can lead to adverse clinical outcomes such as the bowel, 
sexual, urinary dysfunction. Further, due to a prolonged survival and early stage diagnosis of prostate 
cancer, men with prostate cancer can survive up to 10 years without even any aggressive treatment. 
Therefore, the treatment guideline recommends no use of aggressive treatment among those with 
limited survival benefits to avoid risk of adverse effects of treatment (4).   
1.1.5 Prognosis of Prostate Cancer 
With an estimated 27,540 deaths in 2015, prostate cancer is the second-leading cause of 
cancer death in men.  However, in the last decade, the mortality rates among men with prostate cancer 
have declined. (1).  In fact, men diagnosed with prostate cancer have a good survival profile with10-
year relative survival rates (compared to non-cancer cases) range: 90-100%, even without aggressive 
treatments (RP/RT) if diagnosed as localized prostate cancer. However, men with advanced prostate 
cancer have a very poor survival profile with 5-year survival rate of only 23% (1).  Therefore, there 
are needs to develop the strategy to reduce the risk of advanced prostate cancer.  
1.1.6 Chronic Conditions in Prostate Cancer 
Nearly one-third (30.5%) of elderly men with prostate cancer had at least one pre-existing 
chronic conditions. Among those with pre-existing chronic conditions 30% had 2 or more chronic 
conditions (5).  Among elderly men with prostate cancer, the commonly prevalent chronic condition 
was diabetes (13.1%).  Other highly prevalent conditions were: chronic obstructive pulmonary disease 
(COPD) (9.8%), depression (8.0%), congestive heart failure (5.7%), and coronary artery disease 
(2.9%).  
An overwhelming majority of elderly men (84%) died due to causes other than cancer; in the 




cancer (6).  Therefore, an understanding the role of particular types of chronic conditions in prostate 
cancer can provide insight to better manage the chronic conditions as well as prostate cancer.  
1.1.7 Chronic Conditions and Cancer Stage at Diagnosis, Initial Cancer Treatment and Outcomes 
A large body of evidence suggests that men with a greater number of chronic conditions are 
associated with poor clinical outcomes-bowel, sexual and urinary dysfunction as compared to those 
with lower numbers of chronic conditions.  With regards to cancer stage at diagnosis, the conflicting 
evidence exist on the presence of chronic conditions and diagnosis of advanced prostate cancer.  In 
terms of the cancer treatment, guidelines recommend no aggressive prostate cancer treatment with RP 
or RT for individuals with multiple chronic conditions (4, 7). However, in the real-world practice 
settings, mixed evidence exists on receipt of cancer treatment among individuals with chronic 
conditions and prostate cancer (8-10). 
Although elderly men with prostate cancer suffer from different types of chronic conditions, 
the association between the types of chronic conditions on the cancer stage at diagnosis, initial cancer 
treatment and clinical outcomes have not been studied.  Most of the previous studies focused on the 
healthcare outcomes as a function of a co-morbidity index, such as Charlson Comorbidity Index 
(CCI), a numerator for describing weighted/un-weighted number of diseases with little consideration 
of how specific combinations of conditions affected outcomes among the individuals with prostate 
cancer.  Different types of co-occurring chronic conditions may have a differential impact on cancer 
stage at the diagnosis, initial cancer treatment and clinical outcomes among men with prostate cancer.  
Understanding the differential impact is important to develop strategies, which can minimize the 
negative impact of the chronic conditions on prostate cancer care.  
1.1.8 Case of Metformin: Risk of Advanced Stage of Cancer and Cancer Treatment in Prostate 
Cancer and Diabetes  
As stated before, diabetes is highly prevalent among men with prostate cancer (5).  Metformin 
is the first-line of treatment for diabetes with proven safety and efficacy in reducing the risk of 




of metformin, a significant level of experimental evidence suggests the metformin could be associated 
with reduced risk of advanced stage of cancer at diagnosis (11) (12-14) (22) (12).  In addition, it is 
also found to be beneficial alone with primary cancer therapy such as RT in reducing the all-cause 
mortality and cancer-related mortality. Therefore, the use of metformin could influence the initial 
cancer treatment decision.  However, at present, none of the studies have examined the role of 
metformin on the risk of advanced prostate cancer and influence the initial cancer treatment among 
elderly men with prostate cancer.  
1.1.9 Impact of Prostate Cancer Diagnosis on Non-cancer Hospitalizations  
As stated above, nearly one third of elderly men with prostate cancer have pre-existing 
chronic conditions. A diagnosis of incident of prostate cancer may generate the psychological stress 
and if serious enough could lead to cardiovascular events.  The diagnosis of cancer can take the 
attention away from the management of chronic conditions and all attention may be directed towards 
cancer care.  This may lead to worsening of the pre-existing chronic conditions and can increase the 
risk of non-cancer hospitalizations. However, none of the studies assessed the impact of diagnosis of 
prostate cancer on non-cancer hospitalizations among elderly men with incident prostate cancer. An 
analysis of the extent to which cancer diagnosis affects non-cancer hospitalizations and whether the 
impact of cancer on non-cancer hospitalizations varies by chronic conditions will inform the payors, 
program planners and policy-makers and encourage investments in better management of chronic 
conditions.  
1.2 RATIONALE FOR CLASSIFYING TYPES OF CHRONIC CONDITIONS  
As stated above, men with prostate cancer suffer from multiple conditions. However, 
operationalizing the measurement of the types of chronic conditions is challenging.  For example, if  
one tries to study chronic conditions and their combinations using only the sixteen chronic conditions 
captured by the CCI, one can expect 120 two-disease combinations, 560 three-disease combinations, 
1,820 four-disease combinations with more than 20 trillion combinations of chronic conditions 
overall.  If one selects chronic conditions based on 30 chronic conditions of Elixhauser index (15), or 




management (16), one will have even more combinations.  While it is possible to use the number of 
chronic conditions such analyses may not provide any actionable intelligence.  
Therefore, in this dissertation, an attempt is made to define clinically meaningful 
combinations of chronic conditions based on a conceptual framework from the Department of Health 
and Human Services (DHSS) on research, policy, program, and practice (17). Based on this 
framework, the following chronic conditions were selected: diabetes, coronary artery disease, cardiac 
arrhythmia, COPD, asthma, depression, schizophrenia, generalized anxiety disorders, bipolar 
disorders, and psychosis.  
These conditions were grouped based on specific organ domains (22) and synergism in 
treatment patterns and self-management approaches.  For example, management of cardio-metabolic 
conditions such as diabetes and heart disease have similar treatment patterns and self-management 
approaches. Thus, the chronic conditions were grouped into three major domains: cardio-metabolic 
diseases (diabetes, and heart disease), respiratory disease (COPD and asthma), and mental health 
conditions (depression, bipolar disorders, schizophrenia, psychoses, and anxiety).  We classified these 
domains into eight mutually exclusive categories of chronic conditions: (1) cardio-metabolic 
conditions only; (2) mental health conditions only; (3) respiratory conditions only; (4) cardio-
metabolic and mental health conditions, (5) cardio-metabolic and respiratory conditions, (6) 
respiratory and mental health conditions, (7) all the three conditions, and 8) none of the three types of 
chronic conditions. However, one should note that such grouping of chronic conditions reflect the 
presence or absences of multi-organ system conditions, therefore, the types of chronic conditions no 
longer represent the number of chronic conditions. For example, elderly men grouped in the only 
cardio-metabolic conditions group may have three chronic conditions-diabetes, coronary artery 
disease and congestive heart failure, whereas, elderly men with all three types of conditions may also 
have three chronic conditions such as diabetes, COPD and depression.  
1.3 SPECIFIC AIMS 




Specific Aim 1: To examine the associations between the types of pre-existing chronic conditions 
and cancer stage at diagnosis, initial cancer treatment and clinical outcomes after initial cancer 
treatment among fee-for-service Medicare beneficiaries with incident prostate cancer.  
Objective 1.1:  To examine the association between the types of chronic conditions and cancer stage at 
diagnosis among fee-for-service Medicare beneficiaries with incident prostate cancer. 
Hypothesis: Elderly Medicare beneficiaries with only cardio-metabolic, only mental health 
and only respiratory conditions will be more likely to be diagnosed with advanced prostate 
cancer as compared to those with all three-cardio-metabolic, mental health, and respiratory 
conditions.  
Objective 1.2:  To analyze the association between the types of chronic conditions and cancer 
treatment (RP, RT, Hormone therapy and No treatment) among fee-for-service Medicare beneficiaries 
with incident prostate cancer. 
Hypothesis: Elderly Medicare beneficiaries with only cardio-metabolic, only mental health 
and only respiratory conditions will be more likely to receive aggressive treatment (RP/RT) as 
compared to those with all the three types of chronic conditions. 
Objective 1.3: To determine the association between the types of chronic conditions and clinical 
outcomes (bowel, sexual, urinary dysfunctions) after initial cancer treatment among fee-for-service 
Medicare beneficiaries with incident prostate cancer. 
Hypothesis: Elderly Medicare beneficiaries with only cardio-metabolic, only mental health 
and only respiratory conditions will be less likely to have bowel, sexual and urinary 
dysfunctions as compared to elderly men with all the three cardio-metabolic, mental health 
and respiratory conditions. 
Note:  In all the analyses that compared across the types of chronic conditions, the reference group 
was those with all the three types of chronic conditions because the presence of multi-organ system 
chronic conditions were considered as more serious clinical conditions and expected to be associated 
with localized stage at diagnosis, no cancer treatment and poor clinical outcomes as compared to other 
chronic conditions groups.   
Specific Aim 2: To examine the relationship between metformin use and cancer stage at diagnosis, 
and the initial cancer-treatment among elderly (age > 66 years) fee-for-service Medicare 
beneficiaries with pre-existing diabetes and incident prostate cancer. 
Objective 2.1:  To investigate the association between metformin use and cancer stage at diagnosis 
among elderly fee-for-service Medicare beneficiaries with diabetes and incident prostate cancer.  
Hypothesis: Among elderly men with diabetes and incident prostate cancer, metformin users 
will be less likely to be diagnosed with advanced prostate cancer as compared to non-users.  
Objective 2.2:  To analyze the association between metformin use and initial cancer treatment among 
elderly fee-for-service Medicare beneficiaries with diabetes and incident prostate cancer. 
Hypothesis: Among elderly men with diabetes and prostate cancer, metformin users will be 
more likely to receive radiation therapy as compared to non-users; metformin users will be 
more likely to receive hormone therapy as compared to non-users. 
Specific Aim 3: To analyze the impact of cancer diagnosis on the risk of non-cancer 
hospitalizations and evaluate whether the impact of cancer diagnosis on the risk of non-cancer 
hospitalizations vary by the types of pre-existing chronic conditions among fee-for-service 
Medicare beneficiaries with incident prostate cancer.  
Objective 3.1:  To analyze the association between cancer diagnosis and the risk of non-cancer 
hospitalizations by comparing the rates of hospitalizations between the pre- and post-cancer periods 





Hypothesis:  The unadjusted rates and the adjusted risk of non-cancer hospitalizations will be 
higher during the post-cancer period as compared to the pre-cancer period.  
 
Objective 3.2:  To determine the varying associations between the cancer diagnosis and the risk of 
non-cancer hospitalizations by the types of chronic conditions among elderly fee-for-service Medicare 
beneficiaries with incident prostate cancer.  
 
Hypothesis:  Elderly Medicare beneficiaries with pre-existing cardio-metabolic conditions 
will have the greatest increase in the risk of non-cancer hospitalizations (from pre-cancer to 
post-cancer period) as compared to those with other types of chronic conditions. 
  
1.4 DATA SOURCES 
The cancer registry data from the Surveillance, Epidemiology and End Results (SEER) 
program linked with the Medicare administrative claims data were utilized for all the specific aims.  
These data were augmented with the county-level information contained in the Area Health Resource 
Files (AHRF). 
1.4.1 Surveillance Epidemiology and End-Results Registry  
The SEER registries are one of the few resources of population-based cancer data in the US.  
Since 1973, SEER registries have been collecting precise and accurate information on cancer stage, 
treatment, diagnostic procedures, and clinical variables on all newly diagnosed cancer by specific 
regions under the auspices of the National cancer Institute. The SEER data is released with a lag 
period of three years.  At present, the released SEER data contain a total of 7,397,159 malignant cases 
of cancers and majorities of these cancer cases are diagnosed among the elderly population aged 65 
years and over. The SEER data represent 28% of the US population from 18 registries or regions of 
SEER (18).   
The Patient Entitlement and Diagnosis Summary File (PEDSF) file is a customized file from 
the SEER program.  It has information on the cancer diagnosis for up to ten cancers, types of cancers, 
their stages, demographic attributes, marital status, and tumor characteristics at the time of each 





The Medicare is the US Government mandated insurance program covering 97% of the US 
population aged 65 years and older (19).  The NCI links the cases of SEER with Medicare cases using 
an algorithm based on the social security number, last name, first name and birth date of an 
individual. A total of 93% percent of men aged 65 years and older in SEER has been linked to 
Medicare enrollment records (20).  More than 95% of the Medicare beneficiaries receive Part A and B 
coverage benefits. Medicare Part A benefits cover the use of inpatient care in hospitals or skilled 
nursing facilities, home health care, and hospice care, whereas Part B benefits cover the use of 
physician services and outpatient care. However, the Medicare part of data does not capture all the 
claims for the beneficiaries enrolled under the Health Maintenance Organizations (HMOs) as these 
organizations do not have a mandatory requirement to submit all their services claims to Center for 
Medicare and Medicaid (CMS). Therefore, managed care enrollees during the study period were 
excluded from the study.  
SEER-Medicare Linked Data 
A common encrypted identification number is provided for each enrollee so that the PEDSF 
file can be lined with the Medicare files. Medicare data consisted of Medicare Provider Analysis and 
Review (MEDPAR) files, the Carrier Claims (old name Physician/Supplier (NCH)), Outpatient 
(OUTPT), Home Health Agencies (HHA), Hospice, Durable Medical Equipment (DME) and Part D 
Event (PDE).  The MEDPAR file includes Medicare Part A claims records from any short term or 
long term hospital or skilled nursing facility stay from each calendar year, while the outpatient file has 
Part B claims for outpatient visits.  Each record represents an episode of hospital stay, and has up to 
10 diagnoses according to the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM), and 10 ICD-9-CM procedures during each stay, date of admission, the date 
of discharge.  The carrier file represents billing records from physicians and non-institutional 
providers and has procedure codes according to the Healthcare Common Procedure Coding System 




codes with service dates (19).  In the current study, we utilized data from the PEDSF file linked with 
MEDPAR, OUTPT, and NCH files for the years 2000 to 2010.  
1.4.3 Medicare Part-D Data 
Medicare introduced optional/volunteer Part D plans in 2006 that cover prescription drugs 
benefit through enrollment in a Medicare Advantage Prescription drug Plan (MA-PD) or a stand-alone 
drug plan (PDP).  The plan typically starts with an annual deductible, after which Medicare pays for 
the prescription drugs up to an initial coverage limit with certain coinsurance associated with those 
payments. Medicare Part D plans stop payments once individuals reach the annual coverage limit until 
the cost of prescription drugs reaches to catastrophic limit. The phase between the annual coverage 
limit and catastrophic coverage is called "donut hole" or "Medication coverage gap" where enrollees 
have to pay the entire prescription drug costs out-of-pocket (21).  Almost half of the Medicare Part A 
and B enrollee were also enrolled in Part D plans (22).  We utilized the data of the Medicare Part D 
file (PDE) file in addition to PEDSF, MEDPAR, OUTPT and NCH for the years 2007 to 2010.  We 
examined prostate cancer cases diagnosed between 2008 and 2009 so that we could study their 
medication status in a year prior to diagnosis of cancer. 
1.4.4 Area Health Resources Files  
The Area Health Resources Files (AHRF) is a nationwide county-level health resource files in 
the US. The file provides information for about 6,000 county-level variables including healthcare 
facilities, health professionals, resource scarcity, health status, economic activity, health training 
programs and socioeconomic characteristics (23). County-level healthcare resources were derived 
from the Area Health Resource files (AHRF). These included the number of radiation -oncology 
units, and urology units.  The SEER-Medicare files were linked with AHRF using a five-digit Federal 
Information Processing Standard (FIPS) code at the state and county level (23).  
1.5 CONCEPTUAL FRAMEWORK  
The framework of the expanded Behavioral Model of Health Services Use, widely known as 




variables for all our specific aims (24).  The ABM model and adapted versions of this model have 
been extensively used in the health services research to study the factors associated with the 
healthcare service use and healthcare outcomes.   
The ABM model states that the use of healthcare services is determined by individual and 
contextual determinants.  These determinants can be categorized into four groups: 1) Predisposing 
factors: These factors represent the unique feature of individuals that tend to represent more or less 
use the healthcare services. In the current study, we included age, sex, race/ethnicity, marital status of 
the individuals as predisposing factors. 2) Enabling factors: These factors serve as conditions that 
enable individuals to use healthcare services. Based on the model, we considered income, education 
as well as cancer treatment, and medications as potential enabling factors for the healthcare service. 3) 
Need factors: These are the factors requiring the need to use healthcare services at the individual 
level. Based on the definition, we included the presence of chronic conditions and stage of prostate 
cancer as need factors.  4) External environment: These are the set of factors facilitating the use of 
healthcare services related to the structure of services in the geographical areas near to the individuals. 
The presence of healthcare providers in nearby regions such as number of radiation oncologists and 
urologists in the county of residence of the individuals was included as external environment 
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Primary tumor (T) – clinical 
TX Primary tumor cannot be assessed 
 T0 No evidence of primary tumor 
 T1 Clinically inapparent tumor neither palpable nor visible by imaging 
  T1a Tumor incidental histological finding in ≤5% of tissue resected 
  T1b Tumor incidental histological finding in >5% of tissue resected 
  T1c Tumor identified by needle biopsy (e.g. because of elevated PSA)  
 T2 Tumor confined within prostate 
  T2a Tumor involves ≤one-half of one lobe 
  T2b Tumor involves >one-half of one lobe but not both lobes 
  T2c Tumor involves both lobes 
 T3 Tumor extends through the prostate capsule 
  T3a Extrascapular extension (unilateral or bilateral) 
  T3b Tumor invades seminal vesicle(s) 
 T4 Tumor is fixed or invades adjacent structures other than seminal vesicles such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
Regional lymph nodes (N)  
 NX Regional lymph nodes were not assessed 
 N0 No regional lymph node metastasis 
 N1 Metastases in regional lymph node(s) 
Distant metastasis (M) 
 M0 No distant metastasis 
 M1 Distant metastasis 
  M1a Non-regional lymph node(s) 
  M1b Bone(s) 
  M1c Other site(s) with or without bone disease 
    
Table 1. 1 American Joint Committee on Cancer (AJCC)  








Predisposing Enabling Need External 
Environment 
1.1 Cancer Stage Age, 
Race/ethnicity, 
Marital status    
Income, Education, 
Cancer screening, 



























































































































Note: Income and Education were 2000 census-track level data provided in SEER-PEDSF file.  
Number of Urology and Radiation-Oncology units are county-level variables derived from Areas 








Types of Chronic Conditions and Cancer Stage at Diagnosis, Initial Cancer Treatment and 
Clinical Outcomes among Elderly Medicare Beneficiaries with Prostate Cancer 
 
2.1 ABSTRACT  
OBJECTIVE: To examine the associations between types of chronic conditions and cancer stage at 
diagnosis, initial cancer treatment and clinical outcomes among elderly Medicare Beneficiaries with 
prostate cancer.  
METHODS: A population-based observational cohort study was conducted using the Surveillance, 
Epidemiology and End-Results (SEER)-Medicare linked database. The study population consisted of 
elderly men (> 66 years) with prostate cancer diagnosed between 2002 and 2009 (N = 103,820). 
Cancer stage at diagnosis (localized versus advanced) was derived using the American Joint 
Committee on Cancer (AJCC)-Tumor Node Metastasis (TNM) system.  The initial cancer treatment 
was identified during the six months after cancer diagnosis and was categorized in a hierarchical order 
and consisted of: 1) Radical Prostatectomy (RP); 2) Radiation Therapy (RT); 3) Hormone therapy; 
and 4) No treatment. Clinical outcomes (bowel dysfunction (yes/no), sexual dysfunction (yes/no) and 
urinary dysfunction (yes/no)) were measured during one year after the initial cancer treatment.  
Chronic conditions were identified during one year before the date of cancer diagnosis and 
classified as the presence or absence of 1) cardio-metabolic conditions; 2) mental health conditions; 
and 3) respiratory conditions.  These three types of conditions were further classified into the 
following eight mutually exclusive categories: (1) cardio-metabolic conditions only; (2) mental health 
conditions only; (3) respiratory conditions only; (4) cardio-metabolic and mental health conditions; 
(5) cardio-metabolic and respiratory conditions; (6) mental health and respiratory conditions; (7) all 
three- cardio-metabolic, mental health and respiratory conditions; and 8) none of the three types of 
conditions. The independent variables were selected based on the Anderson Healthcare Behavior 
Model (ABM) and consisted of predisposing (age, race/ethnicity, marital status), enabling (income, 
education, access to care, cancer screening), need (number of other chronic conditions), and external-
environment (regions, number of radiation-oncology and urology units in a county of residence) 




Significant differences in cancer stage at diagnosis, initial cancer treatment, and clinical 
outcomes by types of chronic conditions were examined with chi-square tests. Multivariable logistic 
regressions were used to test the adjusted associations between types of chronic conditions and cancer 
stage at diagnosis, and clinical outcomes. Multinomial logistic regression was used to test the adjusted 
associations between types of chronic conditions and receipt of initial cancer treatment. 
RESULTS:  In our study cohort, 46.2% did not have any cardio-metabolic, mental health, and 
respiratory conditions; 35.4% had only cardio-metabolic conditions; 8% had both cardio-metabolic 
and respiratory conditions; 5.2% had only respiratory conditions; 2.1% had both cardio-metabolic and 
mental health conditions; 1.9% had only mental health conditions; and 0.4% had both mental health 
and respiratory conditions.   
Cancer Stage at Diagnosis:  94.6% of the men were diagnosed with localized prostate cancer and 
5.4% were diagnosed with advanced prostate cancer. There was a significant association between 
types of chronic conditions and cancer stage at diagnosis. The highest percentage (5.8%) of advanced 
prostate cancer diagnosis was observed among elderly men with none of the three types of chronic 
conditions. After controlling for predisposing, enabling, need and external environment factors, 
elderly men with none of the three types of chronic conditions were 44% more likely to be diagnosed 
with advanced prostate cancer as compared to men with all the three types of chronic conditions 
(Adjusted Odds Ratio (AOR) = 1.44; 95% Confidence Interval (CI): 1.03, 2.00). 
Initial Cancer Treatment: In our study cohort, 19.7% did not receive any cancer treatment; 46.9% 
received RT; 22% received RP; and 11.4% received hormone therapy.  The highest percentage of no 
prostate cancer treatment (24.4%) was observed among men with all the three types of chronic 
conditions and lowest percentage of no prostate cancer treatment was observed among men with only 
respiratory conditions (18.3%).  In multinomial logistic regression analysis, elderly men with none of 
the three types of chronic conditions (AOR = 1.32; 95% CI: 1.07, 1.61) or only one type of chronic 
physical condition - only cardio-metabolic conditions (AOR = 1.25; 95% CI: 1.02, 1.53) or only 
respiratory conditions (AOR = 1.36; 95% CI: 1.09, 1.69) were more likely to receive RP as compared 




RT.  Additionally, elderly men with cardio-metabolic and mental health conditions or respiratory 
conditions were more likely to receive RT.  Those with only mental health conditions were as likely 
as those with all the three types of chronic conditions to receive initial cancer treatment. There were 
no statistically significant relationships between types of chronic conditions and receipt of only 
hormone therapy among elderly men with prostate cancer.  
Clinical Outcomes: Overall, 14.5% elderly men had bowel dysfunction; 16.1% had sexual 
dysfunction; and 35.0% had urinary dysfunction. In multivariable logistic regression, elderly men 
with none of the three types of conditions (AOR = 1.33; 95% CI: 1.09, 1.63) or only respiratory (AOR 
= 1.26; 95% CI: 1.02, 1.56) or only mental health conditions (AOR = 1.32; 95% CI: 1.05, 1.67) were 
more likely to have sexual dysfunction as compared to those with all the three types of chronic 
conditions. There were no consistent patterns with regard to types of chronic conditions and clinical 
outcomes.   
CONCLUSIONS:   Elderly men with none of the three types of chronic conditions were more likely 
to be diagnosed with advanced prostate cancer.  All chronic condition categories (except for only 
mental health conditions and both mental health and respiratory conditions) were associated with an 
increased likelihood of the initial cancer treatment with either RP or RT as compared to all the three 
types of chronic conditions. Varying associations between types of chronic conditions and clinical 
outcomes were found. 
IMPLICATIONS:  Among elderly men without cardio-metabolic, respiratory and mental health 
conditions, strategies to reduce the risk of advanced prostate cancer are needed.  Although there is no 
evidence that RP or RT can be beneficial in long-term for elderly men with prostate cancer and pre-
existing chronic conditions, an overwhelming majority of men with chronic conditions received 
prostate cancer treatment. Men with prostate cancer and some types of chronic conditions may need 
heightened surveillance, monitoring and therapies to reduce the risk of sexual dysfunction after the 





Chronic conditions are highly prevalent among elderly men diagnosed with prostate cancer in 
the United States (US). Nearly one-third (31%) of elderly men with incident prostate cancer have at 
least one pre-existing chronic condition out of sixteen chronic conditions included in the Charlson 
Comorbidity Index (CCI) (1). The presence of pre-existing chronic conditions can affect the cancer 
stage at diagnosis (2-7), receipt of the initial cancer treatment (8-12) and clinical outcomes such as 
bowel, sexual, and urinary dysfunctions (13-15) among elderly men with prostate cancer. With 
regards to types of chronic conditions, cardio-metabolic conditions (diabetes and cardiovascular 
diseases) are the most common pre-existing chronic conditions (18.1%), followed by respiratory 
conditions (example - chronic obstructive pulmonary disease (COPD) (9.8%), (1) and mental health 
conditions (example - depression) (9%) among elderly men with prostate cancer (16).  Therefore, the 
presence of such different types of chronic conditions can differently influence the development of 
cancer, cancer treatment and outcomes among elderly men with prostate cancer.  
2.2.1 Pre-existing Chronic Conditions and Cancer Stage at Diagnosis  
More than two-third cases of prostate cancer are diagnosed at localized stages (< T2 stage), in 
which tumors are confined to the prostate gland, whereas less than one third of cases of prostate 
cancer are diagnosed at advanced stages where tumors have spread to nearby tissue, bone or organs. 
The diagnosis of prostate cancer at localized stage is desirable as compared to diagnosis of advanced 
stage due to an excellent survival profile with localized stage even without active cancer treatment.  
The presence of chronic conditions can affect the cancer stage at diagnosis for many reasons. There 
are conflicting theories on the relationship between the presence of chronic conditions and risk of 
advanced prostate cancer at diagnosis.  One of these theories hypothesizes that individuals with 
chronic conditions may be less likely to be diagnosed at an advanced prostate cancer because of 
increased contact with the healthcare system for care of their chronic conditions (17). Conversely, the 
theory on competing demand postulates that the care of chronic conditions may take the attention 
away from early symptoms of cancer and that individuals with chronic conditions may be more likely 




chronic conditions on advanced prostate cancer at diagnosis has been documented. For example, men 
with prostate cancer and pre-existing congestive heart failure were more likely to be diagnosed with 
advanced prostate cancer as compared to those without congestive heart failure (2).    
Further, the association between pre-existing chronic conditions and cancer stage at diagnosis 
may differ by types of chronic conditions, due to the differential patho-physiological pathways of 
underlying diseases and prostate cancer. For example, the presence of cardiovascular disease may 
increase the risk of prostate cancer as it shares common risk factors for the development of aggressive 
prostate cancer, such as the presence of high cholesterol level and obesity (18, 19).   Few studies have 
investigated the relationship between specific types of chronic conditions and the cancer stage at 
diagnosis. Findings from these studies suggest that the association between pre-existing chronic 
conditions and cancer stage at diagnosis depends on the types of chronic conditions. For example, 
three studies in the US using the population-level data found that the presence of diabetes was 
associated with an increase in the risk of advanced stage or grade of prostate cancer at diagnosis (20-
22). With respect to the mental health conditions, a retrospective study found that elderly men with 
depression were not more likely to be diagnosed with higher grade of prostate cancer as compared to 
those without depression (9). While these studies have highlighted the relationship between specific 
chronic conditions and cancer stage at diagnosis, many of these studies are outdated, single-
institutional database studies and suffer from the risk of detection bias because screening for prostate 
cancer was not included as one of the independent variables (4-6).  Furthermore, none of these studies 
examined the association between types of chronic conditions combinations and cancer stage at 
diagnosis among elderly men. Understanding the association between types of chronic conditions and 
cancer stage at diagnosis is critical for patient-centered care and individualized treatment (23). 
2.2.2 Pre-existing Chronic Conditions and Prostate Cancer Treatment 
As elderly men with prostate cancer are at greater risk for mortality due to non-cancer 
conditions as compared to risk for mortality due to cancer, the practitioners determine the course of 
cancer treatment after taking into account the presence of pre-existing chronic conditions in addition 




Urology Association (AUA) (24) and the National Cancer Comprehensive Network (NCCN) (25) 
recommend against the use of aggressive treatment such as RP or RT among men who have serious 
chronic conditions.   
2.2.3 Number or Weighted Score of Chronic Conditions 
Some studies have investigated the association between chronic conditions and the use of 
aggressive cancer treatment such as RP or RT among elderly men with prostate cancer.  Using the 
Charlson Comorbidity Index (CCI) score to summarize the impact of chronic conditions, prior studies 
have found varying associations between the presence of chronic conditions and receipt of a particular 
prostate cancer treatment.  Two retrospective studies reported that men with prostate cancer and 
greater CCI scores were less likely to receive RP/RT as compared to those with lower CCI scores (10, 
26). Conversely, two studies reported that men with prostate cancer having greater CCI scores were 
more likely to receive RP/RT as compared to those with lower CCI scores (11) (12).  Finding from 
these studies suggests that weighted summary scores such as CCI may not be useful in determining 
the course of prostate cancer treatment. Therefore, it is important to analyze the relationship between 
specific types of chronic conditions and receipt of a particular cancer treatment among men with 
prostate cancer.   
2.2.4 Presence of a Specific Chronic Condition 
Two previous studies have examined the association between specific chronic conditions and 
prostate cancer treatment. Hall et al. found that men with congestive heart failure were less likely to 
receive surgical therapy as compared to those without congestive heart failure (27). Using the SEER-
Medicare linked data, Prasad et al. reported that men with depression were less likely to receive 
aggressive therapy such as RP or RT as compared to those without depression (6).  While these 
studies suggest the presence of single chronic condition such as congestive heart failure or depression 
would have negative impact on the receipt of RP/RT among men with prostate cancer, these studies 
did not account for the presence of other co-existing chronic conditions.  However, in the real-world 
practice settings, elderly men have multiple chronic conditions which may determine the course of 




chronic conditions and their combinations and receipt of initial treatment for prostate cancer are non-
existent.   
2.2.5 Preexisting Chronic Conditions and Clinical outcomes 
2.2.5.1 Number or Weighted Score of Chronic Conditions:  
 Among elderly men with prostate cancer, pre-existing chronic conditions can affect clinical 
outcomes such as bowel, urinary and sexual dysfunctions.  A handful of real-world observational 
studies have examined the relationship between CCI and the risk of urinary, bowel and sexual 
dysfunctions following the initial cancer treatment among elderly men with prostate cancer.  These 
studies reported that elderly men with higher CCI scores were more likely to have bowel, and urinary 
dysfunctions (13-15, 28) as compared to those with lower CCI scores. Using the SEER-Medicare 
linked data, one study found that CCI scores were not associated with sexual dysfunction (29).  Again, 
the weighted summary scores such as CCI may not be useful in determining strategies for reducing 
the risk of these dysfunctions after the initial cancer treatment. Therefore, it is important to analyze 
the relationship between specific types of chronic conditions and clinical outcomes.   
2.2.5.2 Presence of a Specific Chronic Condition 
A single-institutional study by Hamstra et al. analyzed relationship between the presence of 
myocardial infarction and the risk of bowel dysfunction among men with prostate cancer. The authors 
found that men with myocardial infarction were more likely to have bowel dysfunction during the 
three years after the initial cancer treatment as compared to those without myocardial infarction (13). 
To the best of our knowledge, none of the population-based studies examined the association between 
types of chronic conditions and the clinical outcomes such as bowel, urinary and sexual dysfunction 
among elderly men with prostate cancer. 
Based on the literature review till date, it can be concluded that knowledge gaps exist in how 
specific combinations of conditions affect the cancer stage at diagnosis, the initial cancer treatment 
and the clinical outcomes among elderly men with incident prostate cancer.  Examining the 




treatment and clinical outcomes are important because such analyses can inform the practitioners on 
the management of cancer care in the presence of chronic conditions. Therefore, the primary 
objectives of the current study are to examine the associations between the types of pre-existing 
chronic conditions and cancer stage at diagnosis, initial cancer treatment, and clinical outcomes after 
the initial cancer treatment among fee-for-service Medicare beneficiaries with incident prostate 
cancer. 
2.3 CONCEPTUAL FRAMEWORK 
To accomplish the objectives, the current study adapted the Andersen Behavioral Model, 
which is described in chapter 1. The selected predisposing, enabling, need and external environment-











2.4.1 Study Design  
This study adopted a retrospective cohort design with a baseline and follow-up period.  The 
date of diagnosis of prostate cancer was considered as the index date. The baseline period was defined 
as one year before the index date.  All independent variables were identified during the baseline 
period. For objective 1.2, the follow-up period consisted of 6 months after prostate cancer diagnosis. 
Initial prostate cancer treatment was measured during this period. For objective 1.3, the clinical 
Enabling factors 
(Income, Education, Access to Care) 
Predisposing Factors 
(Age, Race/Ethnicity, Marital status) 
Need factors 
(Types of Chronic Conditions) 
External environment factors  
(Regions, Radiation-Oncology & Urology Unit) 
Initial Cancer Treatment 
Bowel, Sexual and Urinary Dysfunctions 




outcomes were identified during a 12 months after the end of initial prostate cancer treatment (i.e. end 


















2.4.2 Data Sources 
The current study utilized the SEER-Medicare linked database.  The SEER part of the data 
comprised of cancer cases diagnosed with prostate cancer between January 1st 2002 and December 
31st 2009 and linked with Medicare claims of those individuals for the years January 1st 2000 and 
December 31st 2010.  The detailed description of the data sources are provided in Chapter 1.  
 
Diagnosis of Prostate Cancer 
(2002-2009) 
Baseline period:  12-month before cancer 
diagnosis date 
Objective 2.1: Types of Chronic Conditions and Cancer Stage at Diagnosis 
Treatment Period: 6-month 
after cancer diagnosis date    
Baseline period: 12-month before cancer 
diagnosis date  
Objective 2.2: Types of Chronic Conditions and Cancer Treatment 
Follow-up Period: 12-month after Initial 
Cancer Treatment   
Baseline period: 12-month 
2001- 2009 
Treatment Period: 6 month   
Objective 2.3: Types of Chronic Conditions and Clinical Outcomes 




2.4.3 Study Cohort 
The study cohort was based on 358,439 men with an incident diagnosis of prostate cancer. 
Elderly men with multiple cancers (N = 65,794), diagnosed with prostate cancer at the time of autopsy 
or on the death certificate (N = 2,944), younger than 66 years of age (N=97, 159),  died during the 
observation period (N =41, 205), did not have continuous fee-for-service enrollment in Medicare Part 
A and B during the observation period (N = 70,559),  and missing information on cancer stage at 
diagnosis, race, income, education or county of residence (N = 5,390) were excluded.  Thus, the final 
cohort consisted of 103,820 elderly men with incident prostate cancer. Appendix 2.1 depicts the 
analytical population selection process.  
2.4.4 Key Dependent Variables 
2.4.4.1 Prostate Cancer Stage at Diagnosis (Localized and Advanced Stage)  
We utilized the American Joint Committee on Cancer (AJCC) Tumor-Node-Metastases 
(TNM) classifications for staging of prostate cancer.  Based on the TNM systems, we classified cases 
with into two categories: localized and advanced prostate cancer at diagnosis. Localized prostate 
cancer was classified as the cancer with T1 to T2 clinical stage with no regional lymph node (NX-N0) 
or distant metastasis (M0) (24). Advanced prostate cancer was classified as the cancer with T3 or T4 
clinical stage with or without regional lymph node (N1) or distant metastasis (M1). 
2.4.4.2 Initial Cancer Treatment  
The receipt of initial prostate cancer treatment as either receipt of radiation or surgical therapy 
or hormonal therapy was identified using inpatient, outpatient and carrier files with appropriate ICD-9 
CM diagnostic and procedure codes, CPT or HCPCS codes or Revenue Center code during the six 
months after the index date (30, 31),(32).  Appendix 2.2 comprises the details of the codes used to 
identify the initial cancer treatment in the current study.   
We classified elderly men with the initial cancer treatment receipt into four hierarchical 
groups: 1) those who received RP alone or along with any RT or hormone therapy; 2) those who 




3) no-treatment group as those who did not receive RP or RT or hormone therapy during six-month 
after the diagnosis of prostate cancer.  Such grouping of the initial cancer treatment hierarchical 
preference for particular cancer treatments among men with prostate cancer.  
2.4.4.3 Clinical Outcomes-Urinary, bowel, and sexual dysfunction   
Clinical outcomes consisted of bowel, sexual, and urinary dysfunction during one-year after 
the initial cancer treatment. The bowel, sexual and urinary dysfunction were identified using ICD-9 
CM codes and HCPCS codes from the inpatient, outpatient and carrier claims files during one year 
after the initial cancer treatment. Codes used to define urinary, bowel, and sexual dysfunction are 
listed in Appendix 2.3.  Bowel dysfunction included the presence of rectal hemorrhage, ulcers, 
fistulas, hyperbaric oxygen therapy and rectal repairs; and sexual dysfunction included the presence of 
impotence, penile prostheses, and intra-cavernosal injections; (33), whereas, urinary dysfunction 
included the presence of any of the following conditions: incontinence, obstruction, irradiation 
cystitis, bladder hemorrhage, and urinary fistulas (34).  
2.4.5 Key Independent Variable  
2.4.5.1 Types of pre-existing chronic conditions  
 Chronic conditions were identified using one inpatient or two outpatient claims with ICD-9 
CM diagnostic codes and procedure codes during the year before diagnosis of prostate cancer 
(Appendix 2.4).  To define clinically meaningful combinations of chronic conditions, we used several 
criteria.  These included: high prevalence, specific organ domains, common pathophysiology and 
synergistic management of different chronic conditions (35).   Based on prior literature, as well as the 
conceptual model of chronic condition measurement, we selected 12 chronic conditions.  These 12 
chronic conditions were among the 20 conditions selected by the US Department of Health and 
Human Services (DHS) for research, policy, program and practice (36). These 12 conditions were 
grouped into 3 broad categories using specific organ domains, common pathophysiology and 
synergistic management.  They were: cardio-metabolic conditions (diabetes, coronary artery disease, 




depression, schizophrenia, post-traumatic stress disorders, and psychosis) and respiratory conditions 
(COPD and asthma).  Such type of classifications have been used in many studies (37-39). 
Furthermore, we classified these three types of chronic conditions into eight mutual categories: (1) 
cardio-metabolic conditions only (2) mental health conditions only; (3) respiratory conditions only (4) 
cardio-metabolic and mental health conditions; (5) cardio-metabolic and respiratory conditions; (6) 
mental health and respiratory conditions (7) all three -cardio-metabolic, mental health and respiratory 
conditions; and 8) none of the three types of conditions.  
2.4.6 Other Independent Variables  
2.4.6.1 Predisposing Characteristics 
 In the current study, the demographic factors such as age, race/ethnicity, and marital status 
were included as the predisposing characteristics. Age at the time of diagnosis was identified from the 
PEDSF file and was categorized into two groups (66 to 74 years, 75 and above years).  Race/ 
Ethnicity and marital status were also derived from the PEDSF file. Race/Ethnicity was categorized 
into four groups: White, African American, Hispanic, and other. Marital status was categorized into 
four groups: Married, Divorced/Separated, Unmarried, and others.   
2.4.6.2 Enabling Characteristics   
 Enabling factors were income, education, access to care and prostate-cancer screening. The 
PEDSF file contains census-tract level information on income and education variables. Access to care 
was defined using a proxy measure in the absence of any direct measures for the same. The proxy for 
access to care was measured using visits to a primary care provider during the baseline period (40).  
The HCPCS codes of 84152, 84154, 84153, G0103 represented prostate-specific-antigen (PSA) test, 
and these codes were used to identify prostate-cancer screening during the bassline period.    
2.4.6.3 Need Characteristics 
During the baseline period, a very small percentage of men (<5%) had at least one of the 
other forty-two conditions, which were not captured by the cardio-metabolic, mental health, and 




conditions from published literature (41).  The total number of other chronic conditions were 
calculated and categorized into two groups as the presence of either “0-1 condition” or “two or more 
conditions”. 
2.4.6.4 External environment characteristics 
 External environment characteristics comprised of individual’s-resident level county, region, 
county-level radiation oncology units and urology units. The 18 regions of SEER were categorized 
into four groups:1) Northeast-which included two registries of Connecticut, and New Jersey; 2) 
South– which included five registries from Atlanta, Greater Georgia, Kentucky, Louisiana, and Rural 
Georgia,; 3) North-Central which included two registries from Detroit and Iowa;  and 4) West which 
included registries from Arizona, Alaska, Greater California, Cherokee Nation, Hawaii, Los Angeles, 
New Mexico, San Francisco-Oakland, San Jose-Monterey, Seattle-Puget Sound, and Utah (42).  
County-level healthcare resources were derived from the AHRF. The AHRF is a nationwide 
county-level health resource files in the US. The file provides information for about 6,000 county-
level variables including healthcare facilities, health professionals, resource scarcity, health status, 
economic activity, health training programs and socioeconomic characteristics (42).  The number of 
radiation -oncology units, and urology units in counties were used to present county-level healthcare 
resources.  SEER-Medicare files were matched with the AHRF using FIPS state and county codes 
(42). For the purposes of our analyses, the quartiles of radiation-oncology units and urology units at 
the county level were calculated. In addition, the year of diagnosis was also considered as an external 
factor.     
2.5 STATISTICAL ANALYSES 
 The significant differences in predisposing, enabling, need, and external environment 
characteristics by types of pre-existing chronic conditions among the men with incident prostate 
cancer were tested using chi-square tests. Multivariable binary logistic regressions were used to test 
the association between types of chronic conditions and advanced prostate cancer diagnosis after 




Multinomial logistic regressions were performed to test the association between types of chronic 
conditions and cancer treatment receipt (RP, RT, hormone therapy only) after controlling 
predisposing, enabling, need and external environment characteristics.  In this regression, cancer stage 
was additionally included as a need factor.  Separate multivariable binary logistic regressions were 
used to test the associations between types of chronic conditions and clinical outcomes (urinary, 
bowel or sexual dysfunction) after adjusting for predisposing, enabling including the initial cancer 
treatment, need, and external environment characteristics. In these regressions, cancer stage at 
diagnosis was included as a need factor and cancer treatment was included as an enabling factor. All 
statistical analyses were carried out using Statistical Analysis System (SAS) version 9.4 (SAS Institute 
Inc., Cary, NC).   
2.6 RESULTS  
2.6.1 Study Population  
 Table 2.1 summarizes the characteristics of the study cohort (N = 103,820).  A majority of 
men were diagnosed with prostate cancer between age 66 and 74 years (59.7%). The study cohort was 
primarily white (81.7%) and married (67.1%).  Nearly three-quarters of men had at least one primary 
care visit (73.8%) and had a screening of PSA (81.6%) during the baseline period.  
2.6.2 Study Population by Types of Chronic Conditions  
 Table 2.2 reports the characteristics of the study population by types of chronic conditions. 
Overall, 53.8% of the study population had either cardio-metabolic, mental health, or respiratory 
conditions during the year before the prostate cancer diagnosis and 46.2% had none of these 
conditions. The majority of men had only cardio-metabolic conditions (35.4%), followed by men with 
both cardio-metabolic and respiratory conditions (8%), only respiratory conditions (5.2%), cardio-
metabolic and mental health conditions (2.1%), only mental health conditions (1.9%), and mental 
health conditions and respiratory conditions (0.4%).  Significant differences in the predisposing, 
enabling, need and external environment factors by types of chronic conditions were observed among 




2.6.3 Types of Chronic Conditions and Cancer Stage at Diagnosis  
 Table 2.3 describes the relationship between the types of chronic conditions and cancer stage 
at diagnosis. Overall, 94.6% of the study cohort were diagnosed with localized prostate cancer and 
5.4% were diagnosed with advanced prostate cancer.  Significant relationships between types of 
chronic conditions and cancer stage at diagnosis were observed. As compared to men with all the 
three types of chronic conditions (4.5%), a lower percentage of men with cardio-metabolic and 
respiratory conditions were diagnosed (3.8%) with advanced prostate cancer.  
 Table 2.3 also reports the adjusted odds ratios (AOR) and 95% Confidence Intervals (CI) 
from the logistic regression on cancer stage at diagnosis. After adjusting for predisposing, enabling, 
need and external environment factors among elderly men with prostate cancer, elderly men with 
none of the three conditions were 44% more likely to be diagnosed with advanced prostate cancer as 
compared to those with all the three types of chronic conditions (aOR = 1.44, 95% CI = 1.03, 2.00).  
2.6.4 Types of Chronic Conditions and Initial Cancer Treatment Type  
 Tables 2.4 displays the rates of initial cancer treatment by types of chronic conditions. 
Overall, 80.3% of the study population received either RP/RT or hormone therapy during the six 
months after the cancer diagnosis: 22 received RP; 46.9% received RT; 11.4% received hormone 
therapy, and 19.7% received no treatment for cancer.  The highest rate of RP was observed among 
those with only mental health conditions (24.4%), whereas, the highest rate of RT was observed 
among elderly men with cardio-metabolic conditions (49%). The highest rates of only hormone 
therapy (16.2%) or no treatment (24.4%) were observed among elderly men with prostate cancer with 
all the three types of chronic conditions (59.4%).  
  The bottom panel of Table 2.4 displays the AORs and 95% CIs from the multinomial logistic 
regression on initial cancer treatment categories. After adjusting for predisposing, enabling, need 
factors including cancer stage, and external-environment factors, elderly men with none of the three 
types of chronic conditions (AOR = 1.32, 95% CI: 1.07, 1.61) or only cardio-metabolic conditions 




were more likely to receive RP as compared to those with all the three types of chronic conditions.   
These groups were also more likely to receive RT.  Additionally, elderly men with cardio-metabolic 
and mental health conditions (AOR: 1.27 95% CI: 1.04, 1.57) or respiratory conditions (AOR: 1.49, 
95% CI: 1.24, 1.79) were more likely to receive RT. Those with only mental health conditions were as 
likely as those with all the three types of chronic conditions to receive initial cancer treatment. There 
were no statistically significant relationships between types of chronic conditions and receipt of only 
hormone therapy among elderly men with prostate cancer.  
2.6.5 Types of Chronic Conditions and Clinical Outcomes 
 Table 2.5 reports rates of clinical outcomes by the types of chronic conditions. Overall, 
14.5% elderly men had any bowel dysfunction; 16.1% had any sexual dysfunction and 35.0% had any 
urinary dysfunction.  Elderly men with prostate cancer and all the three types of chronic conditions 
had the highest rate of bowel dysfunction (20.5%) whereas, men with mental health conditions had 
the highest rate of sexual dysfunction (17.4%) and men with cardio-metabolic and mental health 
conditions had the highest rates of urinary dysfunction (44.3%). 
 In adjusted analysis, as compared to men with all the three types of chronic conditions, 
elderly men with none of the three types of conditions (AOR = 1.33; 95% CI: 1.09, 1.63) or only 
respiratory (AOR = 1.26; 95% CI: 1.02, 1.56) or only mental health conditions (AOR = 1.32; 95% CI: 
1.05, 1.67) were more likely to have sexual dysfunction. There were no consistent patterns with 
regard to the types of chronic conditions and bowel dysfunction or urinary dysfunction.  
2.7 DISCUSSION 
One in two elderly men (54%) with incident prostate cancer had pre-existing cardio-
metabolic, mental health, and respiratory conditions. The commonly prevalent types of chronic 
conditions were: cardio-metabolic and respiratory chronic conditions (15%). These findings suggest 





2.7.1 Types of Chronic Conditions and Cancer Stage at Diagnosis  
In our study cohort, 1 in 10 elderly men with prostate cancer were diagnosed with advanced 
prostate cancer. Our study estimates are consistent with published literature on rates of advanced 
prostate cancer (6, 9, 43).  A statistically significant association was observed between the absence of 
any three types of chronic conditions and diagnosis with advanced prostate cancer. Closer 
examination of our results suggested that a significantly lower proportion of elderly men with none of 
three types of chronic conditions had a PSA screening and visit to a primary care physician in the year 
before the diagnosis of cancer as compared to those with any other types of chronic conditions. Taken 
together these findings confirm that contact with healthcare system may improve screening for 
prostate cancer (44). Elderly men with cardio-metabolic, respiratory and mental health conditions are 
more likely to use healthcare before diagnosis of cancer as compared to those without these chronic 
conditions leading to higher likelihood of prostate cancer screening.  Therefore, our study findings 
suggest a strong need for the screening those with none of the three common types of chronic 
conditions. 
2.7.2 Types of Chronic Conditions and Initial Cancer Treatment 
Nearly 4 in 5 elderly men with incident prostate cancer received initial cancer treatment.  Our 
findings are consistent with published studies (8, 27).  Elderly men with none of the three types of 
chronic conditions were more likely to receive initial cancer treatment compared to those with all the 
three types of chronic conditions. Clinical guidelines encourage aggressive treatment with RP or RT 
for men without pre-existing chronic conditions because these men are considered relatively healthy 
and therefore may have long-term survival benefit and a better prognosis from initial cancer 
treatment.   
Despite the availability of accurate estimates of survival based on age, CCI score and cancer 
stage (8, 9, 11), in the current study, elderly men with prostate cancer and some types of chronic 
conditions were more likely to be treated for cancer as compared to those with all the three types of 
chronic conditions. These findings suggest that many elderly men with chronic conditions may have 




(45) and may lead to adverse health consequences (46).  The current guidelines for prostate cancer 
treatment recommend “no aggressive treatment should be an option for those with serious chronic 
conditions”.  However, these guidelines did not explicitly define the term “serious chronic 
conditions”.  Therefore, the providers may not consider the presence of some types of chronic 
conditions serious enough and may have treated the cancer aggressively with RP/RT. Our study 
reinforces the need for clinical guidelines that explicitly incorporate the types of chronic conditions 
along with age and life-expectance to recommend cancer treatment options for elderly men with 
prostate cancer. 
Even after controlling for cancer stage and other factors, men with prostate cancer and only 
cardio-metabolic conditions were more likely to receive RP/RT as the initial cancer treatment as 
compared to those with all the three types of chronic conditions. Prior research has shown that elderly 
men with cardio-metabolic conditions may not benefit from cancer treatment as these men are at high 
risk for non-cancer related mortality (8, 45). There is also evidence of the increased risk for adverse 
clinical outcomes such as poor wound healing, risk of perioperative complications due to cancer 
treatment (47, 48) and treatment regret (46) among elderly men with prostate cancer and pre-existing 
cardio-metabolic conditions.  Our study findings highlight the need to increase the physician and 
patient awareness of adverse risks associated with active treatment among elderly men with prostate 
cancer and cardio-metabolic conditions.  
 Another noteworthy finding from this study is that the elderly men with prostate cancer and 
only mental health conditions and both mental health conditions and respiratory conditions did not 
have significant differences between the receipt of RP/RT treatment.  These findings are not 
consistent with a published study in which elderly men with prostate cancer and mental health 
conditions were less likely to receive aggressive treatment compared to elderly men without mental 
health conditions.  The difference in findings could be explained by lack of adjustments for types of 




2.7.3 Types of Chronic Conditions and Clinical Outcomes 
 Consistent with previous studies (13-15), poor clinical outcomes were common among 
elderly men with prostate cancer during the year after the initial cancer treatment. The current study is 
the first of its kind to examine the relationships between types of chronic conditions and clinical 
outcomes.  Elderly men with only mental health conditions and only respiratory conditions were more 
likely to have sexual dysfunction as compared to men with all the three types of chronic conditions. 
Similar to our study finding, Punnen et al. found that the presence of depression was associated with 
sexual dysfunction even after controlling for the primary treatment choice among men with prostate 
cancer in a prospective cohort study (49).   Therefore, our study findings reinforce the need to actively 
monitor men with prostate cancer and only mental conditions or only respiratory conditions for 
reducing the risk of sexual dysfunction. 
Elderly men with prostate cancer and some types of chronic conditions were less likely to 
experience bowel and urinary dysfunction, after controlling for the initial cancer treatment and other 
factors. For example, as compared to those with all the three types of chronic conditions, elderly men 
with prostate cancer and only cardio-metabolic or only respiratory conditions were less likely to have 
bowel and urinary dysfunction.  The reasons for why these particular combinations are associated 
with lower risk of bowel and urinary dysfunction are unknown.  Future research needs to explore the 
possible patho-physiological link between types of chronic conditions and bowel and urinary 
dysfunction. 
 Finally, our study findings have to be interpreted in the context of strengths and limitations. 
Our study is timely and is aligned with the goals of the Office of Cancer Survivorship (OCS) and 
Institute of Medicine (IOM) regarding the management of prostate cancer in the presence of pre-
existing chronic conditions.  To the best of our knowledge, our study is the largest population-based 
registry study to assess the association between the types of chronic conditions and the cancer stage at 
diagnosis, initial cancer treatment and clinical outcomes among elderly men with prostate cancer.  
 As the current study used observational data, the causal associations between the presence of 




study population was restricted to men older than 66 years and older. Therefore, the findings cannot 
be generalizable to younger men with prostate cancer. In addition, as the presence of chronic 
conditions were identified using validated codes from the literature, the clinical severity and 
seriousness of chronic conditions could not be measured which would also be important factors for 
the initial cancer treatment receipt and outcomes among men with prostate cancer.  Furthermore, the 
current study utilized the registry-linked administrative claims data which have either no information 
or limited validity of codes to identify body-mass index, exercise and smoking status, which may be 
associated severity, cancer stage at diagnosis, treatment receipt and clinical outcomes.  
2.8 CONCLUSION 
Elderly men with none of the three types of chronic conditions were more likely to be 
diagnosed with advanced prostate cancer. Therefore, strategies to reduce the risk of diagnosing 
prostate cancer at an advanced stage are needed and tailored to such subgroup of population.   
All chronic condition categories (except for only mental health conditions and both mental 
health and respiratory conditions) were associated with an increased likelihood of initial cancer 
treatment with either RP or RT as compared to all the three types of chronic conditions. Although 
there is no evidence that RP or RT can be beneficial in long-term for elderly men with prostate cancer 
and pre-existing chronic conditions, an overwhelming majority of men with chronic conditions 
received cancer treatment.  Future research is needed to identify the long-term benefit and risk of 
treatment in subgroup of population with different types of chronic conditions.  
Although men with some types of chronic conditions were associated with increased risk of 
sexual dysfunction, no consistent patterns were found for other clinical outcomes by types of chronic 
conditions. Therefore, men with prostate cancer and some types of chronic conditions i.e. mental 
health conditions may need heightened surveillance, monitoring and therapies to reduce the risk of 
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Table 2. 1  
Characteristics of Elderly Medicare Beneficiaries with Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked 
Database-2002-2010 
 Characteristics  Total % 
All  103,820  
Types of Chronic Conditions   
 CM only 36,719 35.4 
 MH only 1,940 1.9 
 RESP only 5,421 5.2 
 CM + MH 2,169 2.1 
 CM + RESP 8,216 7.9 
 MH + RESP 416 0.4 
 None 48,009 46.2 
 All Three 930 0.9 
Predisposing Characteristics 
Age at diagnosis, years   
 66-74 62,020 59.7 
 75+ 41,800 40.3 
Race/ethnicity   
 Whites 84,787 81.7 
 African-American 11,679 11.2 
 Hispanic/Latino 2,148 2.1 
 Others 5,206 5.0 
Marital status   
 Unmarried 6,954 6.7 
 Married 69,628 67.1 
 Divorced/Separated 13,599 13.1 
 Others 13,639 13.1 
Enabling Characteristics 
Quartile of median census 2000 income  
 $ 7- $ 34,522 25,920 25.0 
 $ 34,523-46,224 25,959 25.0 
 $ 46,229-62,764 25,947 25.0 
 $ 62,767-200,008 25,994 25.0 
Quartile of median census 2000 education  
 0 - 8.52 25,946 25.0 
 8.53-15.16 26,057 25.1 
 15.17-26.09 25,821 24.9 
 26.1-100 25,996 25.0 
PSA Screening   
 Yes 84,681 81.6 
 No 19,139 18.4 
Visit to a PCP   
 Yes 76,632 73.8 
 No 27,188 26.2 
Need Characteristics 
Number of Chronic Conditions   
 ≤ One 63,217 60.9 
 > One 40,603 39.1 
    





Table 2. 1  
Characteristics of Elderly Medicare Beneficiaries with Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked 
Database-2002-2010 
 Characteristics  Total % 
External-Environment Characteristics 
SEER-Regions   
 Northeast 20,726 20.0 
 South 25,185 24.3 
 North-Central 12,907 12.4 
 West 45,002 43.3 
Quartile of Radiation Oncology   
 0 to 1 27,475 26.5 
 2 to 6 23,281 22.4 
 7 to 22 27,014 26.0 
 23 to 147 26,050 25.1 
Quartile of Urology Centers   
 0 to 3 25,677 24.7 
 4 to 16 25,467 24.5 
 17 to 44 27,053 26.1 
 45 to 343 25,623 24.7 
Year of diagnosis   
 2002-2005 53,412 51.4 
 2006-2009 50,408 48.6 
Cancer Stage at Diagnosis 
Stage   
 Localized 98,264 94.6 
 Advanced 5,556 5.4 
Initial Cancer Treatment 
Treatment   
 RP 22,864 22.0 
 RT 48,684 46.9 
 Hormone Therapy 11,803 11.4 
 None 20,469 19.7 
Clinical Outcomes 
Bowel Dysfunction   
 Yes 15,043 14.5 
 No 88,777 85.5 
Sexual Dysfunction   
 Yes 16,707 16.1 
 No 87,113 83.9 
Urinary Dysfunction   
 Yes 36,368 35.0 
 No 67,452 65.0 
    
Notes: Based on the data of 103,820 elderly men aged 66 years and older diagnosed with prostate cancer between 
2002 and 2009 using a Surveillance, Epidemiology, and  End-Results (SEER)-linked Medicare data.   
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; PCP: Primary Care Physician; PSA: 
Prostate-Specific Antigen Test; RESP: Respiratory conditions; RP: Radical Prostatectomy; RT: Radiation Therapy
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Table 2. 2  
Characteristics of Elderly Medicare Beneficiaries with Prostate Cancer by Types of Chronic Conditions 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database-2002-2010 
  None CM Only MH only RESP Only CM+ MH CM + RESP MH + RESP All Three Sig. 
  N % N % N % N % N % N % N % N %  
 Overall 48,009 46.2 36,719 35.4 1,940 1.9 5,421 5.2 2,169 2.1 8,216 7.9 416 0.4 930 0.9  
Predisposing Characteristics 
Age at diagnosis, years                 *** 
 66-74 31,152 64.9 20,270 55.2 1,228 63.3 3,258 60.1 1,173 54.1 4,170 50.8 252 60.6 517 55.6  
 75+ 16,857 35.1 16,449 44.8 712 36.7 2,163 39.9 996 45.9 4,046 49.2 164 39.4 413 44.4  
Race/ethnicity                 *** 
 Whites 39,460 82.2 29,827 81.2 1,686 86.9 4,415 81.4 1,813 83.6 6,469 78.7 354 85.1 763 82.0  
 African-American 5,379 11.2 4,143 11.3 159 8.2 581 10.7 198 9.1 1,079 13.1 36 8.7 104 11.2  
 Hispanic/Latino 876 1.8 794 2.2 34 1.8 119 2.2 75 3.5 209 2.5 6 1.4 35 3.8  
 Others 2,294 4.8 1,955 5.3 61 3.1 306 5.6 83 3.8 459 5.6 20 4.8 28 3.0  
Marital status                 *** 
 Unmarried 3,283 6.8 2,167 5.9 218 11.2 414 7.6 193 8.9 554 6.7 47 11.3 78 8.4  
 Married 33,078 68.9 24,782 67.5 1,178 60.7 3,461 63.8 1,282 59.1 5,121 62.3 226 54.3 500 53.8  
 Divorced/Separated 5,934 12.4 4,565 12.4 317 16.3 788 14.5 369 17.0 1,324 16.1 90 21.6 212 22.8  
 Others 5,714 11.9 5,205 14.2 227 11.7 758 14.0 325 15.0 1,217 14.8 53 12.7 140 15.1  
Enabling Characteristics 
Quartile of median census 2000 income               *** 
 $ 7- $ 34,522 11,533 24.0 8,625 23.5 502 25.9 1,624 30.0 627 28.9 2,540 30.9 138 33.2 331 35.6  
 $ 34,523-46,224 11,864 24.7 9,086 24.7 528 27.2 1,436 26.5 522 24.1 2,178 26.5 109 26.2 236 25.4  
 $ 46,229-62,764 12,052 25.1 9,456 25.8 453 23.4 1,262 23.3 509 23.5 1,900 23.1 100 24.0 215 23.1  
 $ 62,767-200,008 12,560 26.2 9,552 26.0 457 23.6 1,099 20.3 511 23.6 1,598 19.4 69 16.6 148 15.9  
Quartile of median census 2000 education               *** 
 0 - 8.52 13,111 27.3 9,001 24.5 508 26.2 1,135 20.9 529 24.4 1,426 17.4 85 20.4 151 16.2  
 8.53-15.16 12,186 25.4 9,337 25.4 490 25.3 1,319 24.3 523 24.1 1,919 23.4 90 21.6 193 20.8  
 15.17-26.09 11,512 24.0 9,331 25.4 473 24.4 1,374 25.3 506 23.3 2,263 27.5 113 27.2 249 26.8  
 26.1-100 11,200 23.3 9,050 24.6 469 24.2 1,593 29.4 611 28.2 2,608 31.7 128 30.8 337 36.2  
PSA Screening                 *** 
 Yes 36,251 75.5 32,144 87.5 1,632 84.1 4,642 85.6 1,852 85.4 7,044 85.7 357 85.8 759 81.6  
 No 11,758 24.5 4,575 12.5 308 15.9 779 14.4 317 14.6 1,172 14.3 59 14.2 171 18.4  
Visit to PCP                
 Yes 32,188 67.0 28,848 78.6 1,568 80.8 4,221 77.9 1,847 85.2 6,798 82.7 356 85.6 806 86.7  
 No 15,821 33.0 7,871 21.4 372 19.2 1,200 22.1 322 14.8 1,418 17.3 60 14.4 124 13.3  
               (Continued…) 
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Table 2. 2  
Characteristics of Elderly Medicare Beneficiaries with Prostate Cancer by Types of Chronic Conditions 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database-2002-2010 
  None CM Only MH only RESP Only CM+ MH CM + RESP MH + RESP All Three Sig. 
  N % N % N % N % N % N % N % N %  
 Overall 48,009 46.2 36,719 35.4 1,940 1.9 5,421 5.2 2,169 2.1 8,216 7.9 416 0.4 930 0.9  
Need Characteristics 
Number of Other Chronic Conditions               *** 
 ≤ One 36,724 76.5 21,031 57.3 1,035 53.4 1,945 35.9 708 32.6 1,618 19.7 80 19.2 76 8.2  
 > One 11,285 23.5 15,688 42.7 905 46.6 3,476 64.1 1,461 67.4 6,598 80.3 336 80.8 854 91.8  
External-Environment Characteristics 
SEER-Regions                 *** 
 Northeast 8,712 18.1 8,347 22.7 342 17.6 953 17.6 439 20.2 1,679 20.4 61 14.7 193 20.8  
 South 11,735 24.4 8,450 23.0 535 27.6 1,538 28.4 507 23.4 2,020 24.6 129 31.0 271 29.1  
 North-Central 5,404 11.3 4,810 13.1 208 10.7 641 11.8 280 12.9 1,361 16.6 61 14.7 142 15.3  
 West 22,158 46.2 15,112 41.2 855 44.1 2,289 42.2 943 43.5 3,156 38.4 165 39.7 324 34.8  
Quartile of Urology Centers                *** 
 0 to 3 12,241 25.5 8,290 22.6 531 27.4 1,593 29.4 511 23.6 2,089 25.4 130 31.3 292 31.4  
 4 to 16 11,985 25.0 9,035 24.6 477 24.6 1,314 24.2 521 24.0 1,839 22.4 112 26.9 184 19.8  
 17 to 44 12,295 25.6 10,000 27.2 491 25.3 1,274 23.5 548 25.3 2,141 26.1 86 20.7 218 23.4  
 45 to 343 11,488 23.9 9,394 25.6 441 22.7 1,240 22.9 589 27.2 2,147 26.1 88 21.2 236 25.4  
Quartile of Radiation Oncology                *** 
 0 to 1 12,994 27.1 8,991 24.5 554 28.6 1,686 31.1 558 25.7 2,254 27.4 140 33.7 298 32.0  
 2 to 6 10,852 22.6 8,305 22.6 452 23.3 1,205 22.2 437 20.1 1,739 21.2 105 25.2 186 20.0  
 7 to 22 12,555 26.2 9,931 27.0 486 25.1 1,287 23.7 569 26.2 1,909 23.2 82 19.7 195 21.0  
 23 to 147 11,608 24.2 9,492 25.9 448 23.1 1,243 22.9 605 27.9 2,314 28.2 89 21.4 251 27.0  
Year of diagnosis                 *** 
 2002-2005 25,127 52.3 18,344 50.0 951 49.0 2,926 54.0 1,039 47.9 4,343 52.9 210 50.5 472 50.8  
 2006-2009 22,882 47.7 18,375 50.0 989 51.0 2,495 46.0 1,130 52.1 3,873 47.1 206 49.5 458 49.2  
                   
Notes: Based on 103,820 elderly men aged 66 years and older diagnosed with incident prostate cancer between 2002 and 2009. Significant group differences by types of chronic    conditions 
combinations were based on Chi-square tests.  
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; PCP: Primary Care Physician; PSA: Prostate-Specific Antigen Test; RESP: Respiratory conditions; 
Sig: Level of Significance; *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05
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Table 2. 3  
Number and Percent with Advanced Prostate Cancer and Adjusted Odds Ratios (AOR) and 95% Confidence 
Intervals from  Logistic Regressions for Advanced Stage Diagnosis among Elderly Medicare Beneficiaries with 
Prostate Cancer Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database 2002-2010 
  Cancer Stage Logistic Regressions on 
Advanced Prostate Cancer Diagnosis 
  Localized Advanced     
  N % N % Sig. AOR 95% CI Sig. 
Types of Chronic Conditions       
 None 45,209 94.2 2,800 5.8 *** 1.44 [1.03 , 2.00] * 
 CM only 34,916 95.1 1,803 4.9  1.29 [0.93 , 1.80]  
 MH only 1,838 94.7 102 5.3  1.33 [0.90 , 1.95]  
 RSP only 5,151 95.0 270 5.0  1.32 [0.93 , 1.88]  
 CM + MH 2,086 96.2 83 3.8  0.89 [0.60 , 1.33]  
 CM + RSP 7,783 94.7 433 5.3  1.37 [0.97 , 1.92]  
 MH + RSP 393 94.5 23 5.5  1.24 [0.71 , 2.17]  
 All Three 888 95.5 42 4.5  Ref   
          
 
Notes: Based on 103,820 elderly men aged 66 years and older diagnosed with prostate cancer between 2002 and 
2009. Significant differences by types of chronic conditions were based on the log-likelihood test using a logistic 
regression for adjusted models and chi-square tests for difference in the rates of stages by types of chronic 
conditions. Adjusted model controlled for predisposing (age, race/ethnicity, marital status), enabling (income, 
education, access to care, cancer screening), need (number of other chronic conditions), and external-environment 
factors (county level-radiation unit, urology units, regions, year of diagnosis)  
 
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; RESP: Respiratory conditions;  
Ref: Reference Group; Sig: Level of Significance; *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2. 4  
Number and Percentage with Initial Cancer Treatment by Types of Chronic Conditions Unadjusted and Adjusted 
Odds Ratios and 95% Confidence Intervals from Multinomial Logistic Regressions among Elderly Medicare 
Beneficiaries with Prostate Cancer Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database 
2002-2010 
   RP RT Hormone  Therapy None Sig. 
    N % N % N % N %   
 All 22,864 22.0 48,684 46.9 11,803 11.4 20,469 19.7  
Types of Chronic Conditions      *** 
 None 11,648 24.3 22,130 46.1 4,553 9.5 9,678 20.2  
 CM Only 7,300 19.9 18,008 49.0 4,487 12.2 6,924 18.9  
 MH Only 473 24.4 819 42.2 221 11.4 427 22.0  
 RESP Only 1,212 22.4 2,537 46.8 678 12.5 994 18.3  
 CM + MH 484 22.3 895 41.3 322 14.8 468 21.6  
 CM + RESP 1,459 17.8 3,758 45.7 1,334 16.2 1,665 20.3  
 MH + RESP 91 21.9 182 43.8 57 13.7 86 20.7  
 All Three 197 21.2 355 38.2 151 16.2 227 24.4  
Adjusted Model-Initial Cancer Treatment (Ref = No Treatment) 
  RP RT Hormone Therapy 
  AOR 95% CI Sig. AOR 95% CI Sig. AOR 95% CI Sig. 
 Types of Chronic Conditions                
 None 1.32 [1.07,1.61] ** 1.44 [1.20,1.71] *** 0.91 [0.73,1.14]  
 CM Only 1.25 [1.02,1.53] * 1.69 [1.41,2.01] *** 1.12 [0.90,1.40]  
 MH Only 1.12 [0.88,1.43]  1.17 [0.95,1.44]  0.92 [0.70,1.21]  
 RESP Only 1.36 [1.09,1.69] ** 1.63 [1.35,1.97] *** 1.11 [0.88,1.40]  
 CM + MH 1.20 [0.95,1.53]  1.27 [1.04,1.57] * 1.14 [0.88,1.48]  
 CM + RESP 1.07 [0.87,1.33]  1.49 [1.24,1.79] *** 1.18 [0.94,1.47]  
 MH + RESP 1.09 [0.75,1.57]  1.31 [0.96,1.80]  1.02 [0.68,1.53]  
 All Three Ref   Ref      
 
Notes: Based on 103,820 elderly men aged 66 years and older diagnosed with prostate cancer between 2002 and 
2009. Significant differences in initial cancer treatment by types of chronic conditions were based on chi-square test. 
Significant differences by types of chronic conditions were based on the log-likelihood test using a logistic 
regression for adjusted model. Adjusted model controlled for predisposing (age, race/ethnicity, marital status), 
enabling (income, education, access to care, cancer screening), need (number of other chronic conditions, cancer 
stage), and external-environment factors (county level-radiation unit, urology units, regions, year of diagnosis)  
  
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; Ref: Reference Group; RESP: 
Respiratory conditions; Sig: Level of Significance; *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 2. 5  
Number and Percentage with Poor Clinical Outcomes Unadjusted and Adjusted Odds Ratios and 95% 
Confidence Intervals from Logistic Regressions of Clinical Outcomes among Elderly Men with Prostate Cancer  
by Types of Chronic Conditions Surveillance, Epidemiology and End Results-Medicare Linked Database 2002-
2010 
  Bowel Sexual Urinary 
  N % Sig. N % Sig. N % Sig. 
 Overall 15,043 14.5  16,707 16.1  36,368 35.0  
Types of Chronic Conditions ***   ***   *** 
 None 5,918 12.3  8,401 17.5  15,247 31.8  
 CM only 5,852 15.9  5,535 15.1  13,680 37.3  
 MH only 335 17.3  338 17.4  731 37.7  
 RESP only 802 14.8  880 16.2  1,866 34.4  
 CM + MH 367 16.9  314 14.5  961 44.3  
 CM + RESP 1,496 18.2  1,063 12.9  3,316 40.4  
 MH + RESP 82 19.7  60 14.4  159 38.2  
 All Three 191 20.5  116 12.5  408 43.9  
Adjusted Odds Ratios and 95% Confidence Intervals  
 AOR 95% CI Sig. AOR 95% CI Sig. AOR 95% CI Sig. 
Types of Chronic Conditions        
 None 0.65 [0.55,0.77] *** 1.33 [1.09,1.63] ** 0.75 [0.65,0.86] *** 
 CM only 0.81 [0.69,0.95] * 1.18 [0.96,1.44]  0.86 [0.75,0.98] * 
 MH only 0.90 [0.73,1.09]  1.32 [1.05,1.67] * 0.89 [0.76,1.04]  
 RESP only 0.70 [0.59,0.84] *** 1.26 [1.02,1.56] * 0.74 [0.64,0.85] *** 
 CM + MH 0.82 [0.67,0.99] * 1.14 [0.90,1.44]  1.08 [0.92,1.26]  
 CM + RESP 0.87 [0.73,1.03]  1.08 [0.87,1.33]  0.89 [0.78,1.02]  
 MH + RESP 0.96 [0.72,1.29]  1.11 [0.79,1.57]  0.83 [0.65,1.05]  
 All Three Ref   Ref   Ref   
           
Notes: Based on 103,820 elderly men aged 66 years and older diagnosed with prostate cancer between 2002 and 2009.  
Significant differences by types of chronic conditions were based on the log-likelihood test using a logistic regression for 
adjusted models and chi-square tests for difference in the rates of stages by types of chronic conditions. Adjusted model 
controlled for predisposing (age, race/ethnicity, marital status), enabling (income, education, access to care, cancer screening, 
cancer treatment), need (number of other chronic conditions, cancer stage), and external-environment factors (county level-
radiation unit, urology units, regions, year of diagnosis) 
 
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health-conditions; RESP: Respiratory conditions; Sig: Level of 
Significance; *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
  
                                                

































Elderly Men diagnosed with prostate cancer as primary cancer at age 
66 years and above, malignant tumor, alive at the time of diagnosis, 
diagnosed during 2002 to 2009, and 
N = 103,820 
 
Reasons for exclusion: 
 Men with carcinoma in-situ (N =40) 
 Men diagnosed with prostate cancer at age 
65 years or younger (N=97,159) 
 
Men with prostate cancer identified using SEER site recode: 54 and 
ICD-10-Code: C61.9 
N =358,439 
Men diagnosed with prostate cancer as a primary cancer and alive at 
the time of diagnosis  
N = 289,701 
 
Reason for exclusion:  
 Men diagnosed with prostate cancer at the 
time of death or autopsy (N= 2,944) 





Men diagnosed with prostate cancer as primary cancer, malignant tumor 
and alive at the time of diagnosis  
N = 192,501 
 Reasons for exclusion: 
 Men with cancer having unclear vital status  
(N =41,205) 
 Men with diagnosed prostate cancer before 
2002 (N = 1) 
 No Part A and B enrollment and enrollment 




Elderly Men diagnosed with prostate cancer as primary cancer at age 66 
years and above, malignant tumor, alive at the time of diagnosis and 
diagnosed between 2002 to 2009  with 18-month continuous eligibility 
in Medicare Part A and B and No HMO enrollment during 1 year 
before diagnosis  N = 109,215 
 
Reasons for exclusion: 
 Missing stage (N=4,852) 
 Missing information on race (N = 87) 
 Missing information on education or 
income  (N = 58) 
 Missing information on county level 
variables (N = 393) 
Appendix 2. 1 Study Cohort Development Flow diagram for Study Population of Elderly Medicare Beneficiaries diagnosed 
with Prostate Cancer  
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Appendix 2. 2  
Codes to Identify Radiation Therapy, Surgery, Hormonal and Chemotherapy Utilization Among Elderly Medicare Beneficiaries with Prostate Cancer 
Using Surveillance, Epidemiology and End Results-Medicare Linked Data 2002-2010 
  Types of Therapy Medicate Claims SEER 













Radical Prostatectomy      
 60.2-60.6  55810, 55812, 55840, 55842, 55845, 
55815, 55866 
30,50,80   
Radiation Therapy      
 9221-9229, 
9227,4604,4610 
V58.0, V66.1, V67.1 55859, 55860,  55862,  55865,  55875 , 
76873 76968, 77261-77299, 77300, 77301 
77305, 77326, 77327,  77328, 77338, 
77401-77499, 77520, 77522, 77523, 
77525, 77750-77799, C1164,  C1174, 
C1325, C1350 C1700-C1712, C1715-
C1720,  C1728 C1790-C1806,  C2638 
C2639,  C2640 C2641, G0256,  G0261, 
Q3001, 0073T 
 1-5, 7 0330 or 0333 
Hormonal therapy       
  62.4  J1950, J9217-J9219, J9202, J9165, 54520, 
54521, 54522, 54530, 54535 
01,   
        
 
Note: 3D-CRT, three-dimensional conformal radiation therapy;  MIRP- Minimum Invasive Robotic Radical Prostatectomy; CPT-4, Current Procedural Terminology, fourth edition; ICD-9, 
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Appendix 2. 3   
Diagnostic and Procedure codes used to Identify Clinical Outcomes-Bowel, Sexual and Urinary Dysfunctions Among Elderly Men with Prostate cancer 
using SEER-Medicare data from the year 2002 to 2010 
  ICD-9 diagnostic codes Procedure codes (ICD-9 procedure codes and HCPCS codes) 
Bowel Dysfunction 
 Ulcer, stricture or 
fistula of rectum or 
anus 
565.1, 569.2, 569.41, 
569.81 
ICD9:56.31,59.8,55.02,55.03,55.12,55.93,55.94,59.93,97.61,97.62, 56.1, 56.41,56.74, 
56.75,56.81,56.84,56.86,56.89,56.91 
HCPCS:50390,50392,50393,50394,50572,50951,50953,50970,50972, 52005,52335, 
50040,50120,50125,50395,50398,50605,52290,52332, 52334,50600,50700, 50715, 
50760,50770,50780,50782,50783,50785, 50800,50810,50815, 50820, 50825,50840 
 Intestinal or vesical 
fistula 
596.1,596.2,599.1,998.6 ICD-9: 54.91,54.0,54.19,59.19 
HCPCS:51715,11950,11951,11952,11954,L8603,51840,51841,53440,  
53442,53445,53447,53449,53443 
 Lymphocele, pelvic 




HCPCS:51715,11950,11952,11954,L8603,51840,51841,53440,53442,  53445, 53447, 
53449, 53443 










607.84 ICD-9: 64.94, 64.95, 64.96, 64.97  HCPCS: 54400, 54401, 54402, 54405, 54407, 54408, 














Stricture 593.3, 598.0, 598.00, 598.01, 
598.1, 598.2, 598.8, 598.9, 599.2, 
599.4 
 
 Cystitis, hematuria 595.1, 595.3, 595.82, 595.89, 
595.9, 596.7, 




HCPCS: 52000, 52001, 52214, 52224 
                                                






















Obstruction 593.4, 596.0, 596.3, 596.4, 596.5, 
596.51, 596.52, 596.53, 
596.54, 596.55, 596.59, 596.6, 
596.8, 596.9, 599.6 
ICD-9 : 55.02, 55.03, 55.12, 55.93, 55.94, 56.1, 56.31, 56.41, 56.74, 56.75, 56.81, 56.86, 
56.89, 56.91, 57.0, 57.11, 57.12, 57.17, 57.18, 57.19, 57.21, 57.22, 57.4, 57.41, 57.49, 57.82, 
57.85, 57.89, 57.91, 57.92, 57.93, 57.94, 57.95, 58.0, 58.1, 58.31, 58.39, 58.44, 58.46, 58.47, 
58.5, 58.6, 58.99, 59.8, 59.93, 59.94, 60.21, 60.29, 60.95, 97.61, 97.62, 97.63, 97.64, 97.65, 
97.69, 98.19 
HCPCS: 50040, 50120, 50125, 50390, 50392-50395, 50398, 50572, 50600, 50605, 50700, 
50715, 50760, 50770, 50780, 50782, 50783, 50785, 50800, 50810, 50815, 50820, 50825, 
50840, 50951, 50953, 50970, 50972, 51040, 51520, 51600, 51705, 51800, 51820, 51880, 
52005, 52275, 52276, 52281-52283, 52290, 52310, 52332, 52334, 52335, 52500, 52601, 
52612, 52614, 52620, 52620, 52630, 52640, 53000, 53010, 53020, 53400, 53405, 53410, 






599.82, 788.3, 788.30, 788.31, 
788.32, 788.33, 788.34, 788.35, 
788.36, 788.37, 788.38, 788.39 
ICD-9: 58.93, 58.99, 59.3, 59.4, 59.5, 59,6, 59.7, 59.71, 59.72, 59.79 
HCPCS: 11950, 11951, 11952, 11954, 51701, 51715, 51840, 51841, 51990, 51992, 53431, 




Fistula 596.1, 596.2, 599.1, 998.6 ICD-9: 56.84, 57.83, 57.84, 58.43 
HCPCS: 45800, 45805, 45820, 45825, 50920, 50930, 53520 
 Miscellaneous supplies  HCPCS:E0740,A4335,A5149 
    
                                                




Appendix 2. 4 
Codes Used to Identify the Types of Chronic Conditions and List of Other Chronic Conditions Among 
Elderly Medicare Beneficiaries with Incident Prostate Cancer Surveillance, Epidemiology, End-Results-
Medicare Linked Data of 2002 to 2009 
Types of Chronic Conditions ICD-9 Diagnostic Codes 
Cardio-metabolic Conditions  
 Coronary Artery Disease 410,411,412,413, 414,    
 Congestive Heart Failure 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 428 
 Conductive Disorders 423, 427.31 
 Diabetes 250 
Mental Health Conditions  
 Depression 296.2, 296.3, 311,300.4,311, 300.4 
 Bipolar Disorders 296.0, 296.1, 296.4, 296.5, 296.6,296.7, 296.8, 296.9 
 Schizophrenia 297, 298, 299 
 Psychoses 309.81 
 Anxiety 300.0, 300.2,300.3 
Respiratory Conditions  
 COPD and other pulmonary conditions 490, 491, 492, 495, 496, 500, 501, 502, 503, 504, 505, 506.4 
 Asthma 493 
List of other Chronic Conditions  
Abuse of drugs,  Acute Renal Failure, AIDS, Alcohol abuse, Amputations, Blindness, Cerebrovascular Disease, 
Chronic Renal Failure, Cognitive impairment, Dementia, Diverticulitis, End-stage kidney disease, End-stage liver 
disease, Epilepsy, Gallstones, Gangrane, Gastritis, Gastroparesis, GERD, Gout, Hemiplegia, Hip Arthoplasty, Low 
Back Pain, Multiple sclerosis, Muscular Dystrophy, Nephropathy, Nephrotic syndrome, Osteoarthritis, Parkinson’s 
Disease, Peptic Ulcers, Peripheral Vascular Disease, Retinopathy, Rheumatoid Arthritis, Spinal Cord Injury 
Systemic Lupus Erythematous, Ulcer, Viral Hepatitis 
  




Association between Metformin Use and Cancer Stage at Diagnosis and Initial Cancer Treatment 
among Elderly Medicare Beneficiaries with Diabetes and Prostate Cancer 
 
3.1 ABSTRACT 
OBJECTIVE: To examine the associations between metformin use and cancer stage at diagnosis and the 
initial cancer treatment among elderly men with pre-existing diabetes and incident prostate cancer.  
METHODS: A population-based observational cohort study was conducted using the Surveillance, 
Epidemiology and End-Results (SEER) –Medicare linked database. The study population consisted of 
elderly men (> 66 years) with pre-existing type 2 Diabetes Mellitus (T2DM) and incident prostate cancer 
between January 2008 and December 2009 (N = 2,652).  Cancer stage at diagnosis was categorized into 
two groups (localized and advanced) based on the American Joint Cancer Committee Tumor-Node-
Metastasis (TNM) System classification.  The initial cancer treatment during the six months after cancer 
diagnosis was categorized into four groups using a hierarchy: 1) receipt of radical prostatectomy (RP); 2) 
receipt of radiation therapy (RT); 3) receipt of only hormone therapy; and 4) no cancer treatment.    
The key independent variable, metformin use, and other independent variables were measured 
during the one year period before cancer diagnosis. The independent variables were selected using the 
Anderson Behavior and Healthcare Utilization Model and consisted of predisposing (age, race/ethnicity, 
and marital status), enabling (income, education, access to care,), need (severity of diabetes, cancer stage, 
insulin and other medication use), and external environment factors (region, number of urology and 
radiation-oncology units measured at the county-level).  
Significant unadjusted associations between metformin use and cancer stage at diagnosis and the 
initial cancer treatment were examined using chi-square tests. The adjusted association between metformin 
use and cancer stage diagnosis was analyzed using logistic regression after controlling for predisposing, 
enabling, need, and external environment-related factors. The adjusted association between metformin use 
and the initial cancer treatment was analyzed using multinomial logistic regression. The reference group 
for the dependent variable was “no cancer treatment.”  To control for the observed selection bias in 
metformin use, inverse probability treatment weights (IPTW) were constructed using logistic regression on 
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metformin use.  The IPTWs were used in analyses related to the stage of cancer diagnosis and the initial 
cancer treatment.   
RESULTS: In the study cohort, 35.7% used metformin during the year before diagnosis of prostate cancer. 
Significant associations were observed between predisposing, enabling, need, and external environment 
factors and metformin use, suggesting the presence of observed selection bias between metformin users 
and non-users. Overall, 93.7% of the study population had a diagnosis of localized prostate cancer and 
6.3% had a diagnosis of advanced prostate cancer. A significantly lower percentage of metformin users 
were diagnosed with advanced prostate cancer as compared to non-users of metformin (4.7% vs. 6.7%, p< 
0.03).  After controlling for the observed selection bias and other independent variables,  metformin use 
was significantly associated with a reduction in the risk of advanced prostate cancer (Adjusted Odds Ratio, 
AOR: 0.68, 95% Confidence Interval, CI:  0.48, 0.97).  
Overall, 72.4% of the study population received either RP (17.4%), RT (46.5%) or hormone 
therapy (8.6%) during the six months after the diagnosis of prostate cancer.  A higher percentage of 
metformin users as compared to non-users received RP (21.3% vs 16.3%, p < 0.001). After adjusting for 
the observed selection bias and other independent variables, metformin users were 45% more likely to 
receive RP as compared to non-users (AOR = 1.45, 95% CI = 1.14, 1.86).   
CONCLUSIONS: Among elderly men with T2DM and incident prostate cancer, metformin use was 
associated with a reduction in the risk of advanced prostate cancer.  Metformin users were more likely to 
receive RP as compared to non-users.  No statistically significant relationships were observed between 
metformin use and RT or hormone therapy.   
IMPLICATIONS: The findings from the current study add to the nascent literature on the association 
between metformin use and the risk for advanced cancer stage and treatment based on observational data.  
Well-designed, randomized clinical trials are needed to confirm the causal link between metformin use and 
stage of prostate cancer diagnosis.   
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3.2 INTRODUCTION 
Individuals with diabetes, specifically those with type 2 diabetes mellitus (T2DM) have a higher 
risk for many cancers such as breast, colon and rectum, endometrium, liver and pancreatic cancers as 
compared to those without diabetes (1) due to biological mechanisms and shared risk factors (2-4).  In pre-
clinical studies, T2DM has been found to be associated with increased levels of plasma insulin, insulin 
resistance and hyperglycemia, which may have a direct effect on the growth of tumors (5, 6) leading to the 
development of many types of cancers (1).   
3.2.1 Diabetes and Prostate Cancer Risk and Stage at Diagnosis 
In the case of prostate cancer, an inverse relationship between diabetes and cancer risk has been 
observed (3).  However, among men who developed prostate cancer, diabetes was associated with an 
advanced stage of cancer diagnosis (7, 8). Three population-based studies in the Unites States (US) 
reported that the presence of diabetes was associated with an increased risk for advanced prostate cancer 
measured either by stage or tumor grade. In case-control studies and cohort studies, men with diabetes 
were less likely to be diagnosed with localized stage of prostate cancer.  The risk ratio (RR) was 0.70, 95% 
CI = 0.56-0.86 for case-control studies and the RR was 0.72, 95% CI 0.67, 0.77 for cohort studies (7). 
Although the exact biological mechanisms for the link between diabetes and prostate cancer are not known, 
it is speculated that men with diabetes have low levels of androgen, which may be associated with 
advanced stage of cancer at diagnosis (7, 8).  
3.2.2 Anti-diabetes Drugs (Metformin) and Cancer Stage at Diagnosis 
The main modality of treatment for diabetes is pharmacotherapy with anti-diabetes drugs such as 
metformin, thiazolidinediones, sulfonylureas, and insulin. All classes of anti-diabetes drugs may indirectly 
affect the risk of prostate cancer by controlling hyperglycemia.  Of special interest is the use of metformin 
for diabetes management because of its unique actions on insulin resistance and hyperinsulinemia (9) as 
well as its anti-cancer properties (10-12).  A systemic review found that metformin use reduced the risk of 
prostate cancer among men with diabetes (13) perhaps by regulating adenosine monophosphate-activated 
protein kinase (AMPK) pathways (10) and mammalian target of rapamycin (mTOR) (12). Based on pre-
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clinical evidence, one can speculate that metformin may also reduce the risk of advanced prostate cancer 
among men with diabetes and incident prostate cancer (14). This relationship between metformin and 
advanced prostate cancer diagnosis was explored by one population-based study from Canada (15). The 
study investigators used a cohort of 119,315 men with diabetes and measured cancer stage using tumor 
grade.  After adjusting for other risk factors, the investigators concluded that metformin use was not 
associated with the advanced form of cancer diagnosis (23). The investigators of the study did not control 
for severity of diabetes, which may have affected the findings. Controlling for diabetes severity is 
important because individuals with severe diabetes have micro and macro-vascular complications and may 
have adverse pathological profiles (16). Therefore, diabetes severity may alter the relationship between 
metformin use and cancer stage at diagnosis.  Furthermore, the study did not control for the observed 
selection bias between metformin users and non-users; such bias may lead to misleading findings on the 
association between metformin use and cancer stage at diagnosis. Thus, there is a need for population-
based studies to examine the relationship between metformin use and cancer stage at diagnosis that control 
for a comprehensive set of risk factors and the observed selection bias between metformin users and non-
users.   
3.2.3 Metformin Use and the Initial cancer treatment 
Metformin use may also affect the types of initial cancer treatment.  The initial cancer treatment is 
often determined by the stage of diagnosis, life expectancy of an individual and pre-existing chronic 
conditions (17).  However, in the light of recent findings about the anti-cancer properties of metformin, 
physicians may take into account the use of metformin when deciding the types of initial cancer treatment 
among men with diabetes and prostate cancer.  For example, metformin down regulates the androgen-
receptors levels, which in turn maximizes the anti-cancer properties of hormone therapy (18).  Radiation 
therapy along with metformin has been found to inhibit the progression of cancer and reduce mortality 
among men with prostate cancer (19).  Therefore, among men with prostate cancer and diabetes, metformin 
users may be more likely to receive radiation therapy or hormone therapy as compared to non-users. 
However, there are no population-based studies examining the association between metformin use and the 
types of initial cancer treatment among men with diabetes and incident prostate cancer.   
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Therefore, the primary objective of the study is to investigate the association between metformin 
use and cancer stage at diagnosis and the initial cancer treatment among elderly fee-for-service Medicare 
beneficiaries with T2DM and incident prostate cancer.   
3.3 CONCEPTUAL FRAMEWORK 
We utilized the ABM model (20) described in chapter 1, for selection of independent variables. 











3.4.1 Study Design  
A cohort study design was adopted with a baseline and a follow-up period as depicted in Figure 
3.2. The index date was defined as the date of diagnosis of prostate cancer.  The baseline period consisted 
of 12 months before the index date and the follow-up period consisted of 6 months after the index date.  
Diabetes, metformin use and other independent variables were identified during the baseline period.  The 





(Income, Education, Cancer Screening, PCP visit) 
Predisposing Factors 
(Age, Race/Ethnicity, Marital status) 
Need factors 
(Severity of Diabetes, Insulin, Statin, Steroid Use) 
External environment factors  
 (Regions, Urology and Radiation Oncology Units) 
Initial Cancer Therapy 
Figure 3.1: Study Theoretical Framework: Adaptation of Andersen Behavioral Model for Aim 2 
  














3.4.2 Data Source 
Data were derived from the SEER-Medicare linked database, details of which are provided in the 
Chapter 1.  
3.4.3 Study Cohort 
  The study cohort comprised of 74,791 men with incident prostate cancer diagnosed between 2008 
and 2009. We excluded 7,763 cases for the following reasons: diagnosis of prostate cancer during the 
autopsy; the presence of multiple cancers; carcinoma in-situ; aged 65 years and younger; died during the 
study period; enrolled in Medicare Health Maintenance Organizations; not continuously enrolled in 
Medicare PART A, B, and D during the study period, and missing cancer stage at diagnosis. The details on 
the study cohort selection process are provided in Appendix 3.1. 
After all the exclusions, the final study cohort consisted of 2,652 elderly men with Type 2 diabetes 
Mellitus (T2DM) and incident prostate cancer. The presence of T2DM was identified using at least one 
inpatient visit or two or more physician visits with a primary or a secondary diagnosis codes for T2DM 
(ICD-9-CM codes: 250. x0 or 250. x2) during the baseline period.   
Baseline period: 12-month 
Index date: Diagnosis date of Prostate 
Cancer (2008-2009) 
Treatment Period: 6 Month   Baseline period: 12-month 
 2007-2009 
Index date:   
Objective 2.1: Metformin Use and Cancer Stage at Diagnosis 
Objective 2.2: Metformin Use and Initial Cancer Treatment 
Figure 3. 2 Schematic Presentation of Study Design for Aim 2 
  
Page | 57  
 
3.4.3 Key Dependent Variable  
3.4.3.1 Cancer Stage at Diagnosis 
The American Joint Committee on Cancer (AJCC) Tumor-Node-Metastases (TNM) classification 
was used to identify the stage of prostate cancer from the PEDSF file.  Based on the AJCC-TNM systems, 
men were classified as having localized cancer stage if they had T1 or T2 clinical stage with no regional 
lymph node (NX-N0) involvement and absence of any distant metastasis (M0) (21).  Men were classified 
as having advanced cancer if they were diagnosed with T3 or T4 clinical stage with or without regional 
lymph node (N1) or distant metastasis (M1).   
3.4.3.2 The initial cancer treatment  
The initial cancer treatment categories were identified using both SEER-PEDSF file and inpatient, 
outpatient and carrier files using validated algorithms (22, 23, 24) during the follow-up period.  The details 
on diagnosis and procedure codes used to identify types of cancer treatment are provided in Appendix 2.2. 
The initial cancer treatment receipt was classified using a hierarchy.   Men who received radical 
prostatectomy (RP) were classified into one group; among men who did not receive RP, receipt of 
radiation therapy (RT) was considered; among men who did not receive RT, hormone therapy was 
considered.  The final classification consisted of men who: 1) received RP; 2) received RT alone or RT 
with hormone therapy; 3) those who received only hormone therapy, and 4) those who did not receive any 
RP, RT or hormone therapy.  This hierarchical classification was adopted to reflect clinical practices in the 
real-world settings (25, 26) .  
3.4.4 Key Independent Variable 
3.4.4.1 Metformin Use 
Metformin use was identified using the Medicare Part-D files.  Metformin prescriptions were identified 
using the national drug codes (NDCs). Men with at least one prescription for metformin during the baseline 
period were considered as metformin users and men without any prescriptions for metformin were 
considered as non-users.  
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3.4.5 Other Independent Variables 
3.4.5.1 Predisposing characteristics  
Predisposing characteristics consisted of age at diagnosis, race, and marital status.  These were 
identified from the PEDSF file.  Age at the time of diagnosis was categorized into two groups (66 to 74 
years, > 75 years).  Race/ethnicity was categorized into four groups: White, African American, Latino, and 
other. Marital status was categorized into four groups: Married, Divorced/Separated, Unmarried, and 
Others.   
3.4.5.2 Enabling characteristics 
Enabling characteristics were: education, income, PSA test, visits to primary care physicians, and 
medication coverage gap. Median income and median education at the census tract of residence were 
derived from the PEDSF file. Income and education were measured by quartiles. The receipt of PSA test 
was identified using the following HCPCS codes: 84152, 84153, 84154, and G0103 using the Medicare 
carrier files during the baseline period.  The presence or absence of primary care visits during the baseline 
was identified using the provider specialty codes (27).  
Medication coverage gap (i.e. donut hole) was identified at the time of prostate cancer diagnosis.  
Coverage gap was defined as follows: 1) donut hole not reached at the time of cancer diagnosis; 2) in donut 
hole at the time of cancer diagnosis; and 3) out of donut hole at the time of cancer diagnosis. 
3.4.5.3 Need characteristics 
The severity of diabetes, insulin use, statins use and corticosteroid use were considered as need 
factors. The Diabetes Complications Severity Index (DCSI) was calculated using the modified algorithm 
by Chang et al. (28).   The DSCI is based on seven categories:  retinopathy, nephropathy, neuropathy, 
cerebrovascular, cardio-vascular, peripheral vascular disease, and metabolic conditions. Based on the 
severity of particular types of complications, a score of 1 or 2 were assigned to each of the seven 
categories, with a total DCSI score ranging from 0 to 13. The DCSI scores were grouped into quartiles. 
Details of the ICD-9-CM codes and the scoring algorithm are provided in Appendix 3.2.  The use of 
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insulin, statins, and corticosteroids were identified using the NDCs recorded in the Medicare Part D files 
during the baseline period. 
3.4.5.4 External environment characteristics  
The SEER data has 18 registries/regions which were categorized into four regions:1) Northeast 
with two registries of Connecticut, and New Jersey; 2) South, with five registries of Kentucky, Louisiana, 
Atlanta, Rural Georgia, Greater Georgia; 3) North-Central with two registries of Detroit and Iowa;  and 4) 
West with Hawaii, New Mexico, Seattle-Puget Sound, Utah, San Francisco-Oakland, San Jose-Monterey, 
Los Angeles, Greater California, Arizona, Alaska, and Cherokee Nation (29). The number of radiation 
oncology units, and urology units at the county-level (converted into quartiles) were also included (29). 
 3.5 STATISTICAL ANALYSES 
Significant group differences in the study population characteristics by metformin use was 
examined with chi-square tests.  A binary logistic regression was used to determine the associations 
between predisposing, enabling, need, and external environment characteristics and metformin use. C-
statistics and area under the curve were used to assess the model fit. Logistic regression was used to derive 
inverse probability treatment weights (IPTW) and these IPTWs were used to control for the observed 
selection bias in regressions on the cancer stage and the initial cancer treatment.  
Significant unadjusted associations between metformin use and cancer stage at diagnosis and the 
initial cancer treatment were examined with chi-square tests.  The IPTW-adjusted multivariable logistic 
regression and multinomial logistic regression were used to analyze the relationship between metformin 
use and cancer stage at diagnosis and the initial cancer treatment respectively.  As the odds ratios and 
relative risk are approximately similar for the events with low prevalence such as advanced prostate cancer 
(≤ 10%) (30), these terms risk ratio or odds ratio of advanced prostate cancer were used interchangeably. 
All statistical analyses were carried out using Statistical Analysis System (SAS) version 9.4 (SAS Institute 




Page | 60  
 
3.6 RESULTS  
3.6.1 Description of the Study Cohort  
The study cohort consisted of 2,757 elderly men with pre-existing diabetes and incident prostate 
cancer between 2008 and 2009.  Table 3.1 represents the characteristics of the study cohort. An 
overwhelming majority of men were whites (92.3); 59.7% were diagnosed with prostate cancer between 
the ages of 66 and 74 years; 58.6% were married and 46.2% resided in the Western region of the US. 
Nearly three-quarters (70.0%) of study cohort had a primary care visit.  An overwhelming majority 
(91.1%) had PSA tests during the baseline period.    
3.6.2 Description of the Study Cohort by Metformin Use 
 Table 3.1 also summarizes the characteristics of the study cohort by metformin use. Overall, 
35.6% of the study cohort had at least one prescription of metformin during the baseline period.  
Significant differences in predisposing, enabling, need and external environment factors by metformin use 
were observed.  
Table 3.2 describes the adjusted odds ratios (AOR) and 95% CI for the metformin use among 
elderly men with diabetes and prostate cancer. Elderly men aged 66 to 74 years as compared to those with 
75 years and older (AOR: 1.31, 95% CI: 1.10, 1.56), Latinos as compared to Whites (AOR: 1.62, 95% CI: 
1.12, 2.34), those who received insulin as compared to no insulin (AOR: 2.95, 95% CI: 1.94, 4.49), those 
who received statins as compared to no statins (AOR: 1.94, 95% CI: 1.63, 2.31) were more likely to 
receive metformin. Whereas, elderly men with a severe DCSI score (4 to 13) were less likely to receive 
metformin as compared to those with zero or one DCSCI score (AOR: 0.65, 95% CI: 0.51, 0.84).  
3.6.3 Metformin and Cancer Stage at Diagnosis 
 Table 3.3 describes the relationship between metformin use and cancer stage at diagnosis among 
elderly men with prostate cancer and diabetes. Overall, 93.7% of the study population were diagnosed with 
localized prostate cancer; 6.3% were diagnosed with advanced prostate cancer. We did not observe a 
statistically significant difference in the rates of localized or advanced prostate cancer at diagnosis by 
metformin use.  
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 Table 3.3 also reports unadjusted odds ratios (OR) and adjusted ORs (AOR) from IPTW logistic 
regressions for the advanced prostate cancer among elderly men with diabetes and prostate cancer.  In 
unadjusted logistic regression, we observed a significant association between metformin and risk of 
advanced prostate cancer at diagnosis (OR: 0.69, 95% CI: 0.49, 0.95).  After adjusting for predisposing, 
enabling, need and external-environment factors among elderly men with prostate cancer and diabetes, 
metformin use was significantly associated with a reduction in the risk of advanced prostate cancer (AOR: 
0.68, 95% CI: 0.48, 0.97). 
3.6.4 Metformin and the Initial Cancer Treatment  
 Overall, 72.4% of the study population received either RP/RT or hormone therapy during the six 
months after the cancer diagnosis. RT was the most received initial cancer treatment in the study 
population (46.5%), followed by RP (17.4%) and only hormone therapy (8.6%).  Nearly one quarter of the 
study population did not receive any cancer treatment.  A greater proportion of the elderly men using 
metformin received RP (21.3%) as compared to those who did not use metformin (16.6%), whereas, a 
lower proportion of elderly men using metformin (23.8%) did not receive any cancer treatment as 
compared to those who did not use metformin (28.5%).  
Table 3.4 displays the ORs and AORs from multinomial logistic regressions on the receipt of 
active treatment of either RP, RT or only hormone therapy among elderly men with prostate cancer and 
diabetes. In unadjusted analysis, metformin users were 54% more likely to receive the RP as the initial 
cancer therapy (OR: 1.54, 95% CI: 1.24, 1.92), and RT (OR: 1.20, 95% CI: 1.04, 1.44) as compared to 
non-metformin users among elderly men with prostate cancer. Even after controlling for predisposing, 
enabling, need and external environment-related factors, metformin users were 45% more likely to receive 
RP as compared non-metformin users among elderly men with diabetes and prostate cancer (AOR: 1.45, 
95% CI: 1.14, 1.86). The use of metformin was not associated with RT or only hormone therapy among 
elderly men with diabetes and prostate cancer.   
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3.5 DISCUSSION  
The current study is the first largest population-based study to examine whether the risk of 
advanced prostate cancer diagnosis is reduced with metformin use among elderly men with pre-existing 
T2DM and incident prostate cancer in the US. After controlling for the observed section bias between 
metformin users and non-users and other independent variables, the risk for advanced stage cancer 
diagnosis is reduced with metformin use among elderly men with T2DM and incident prostate cancer.  The 
current study addressed the limitations of the single population-based examination of metformin use and 
the cancer stage by incorporating a validated diabetes severity complications index and controlling for the 
observed selection bias.  The current study findings are consistent with the pre-clinical evidence on the role 
of metformin in prevention of advanced prostate cancer (22) (10). If the findings of the current study are 
confirmed by other population-based studies, randomized clinical trials can be conducted to establish the 
causal link between metformin use and risk of advanced prostate cancer diagnosis.    
With regards to the initial cancer treatment, the current study findings revealed that the initial 
cancer treatment with RP or RT or hormone therapy was very common (72.4%) among elderly men with 
T2DM and incident prostate cancer. In the absence of clear guidelines for management of prostate cancer 
among men with diabetes, the choice of initial cancer treatment has been a subject of debate.  Active 
treatment is often not preferred because elderly men with T2DM and incident prostate cancer may be at 
higher risk for mortality due to cardiovascular conditions than morality due to prostate cancer (31). 
Additionally, RP can lead to increased surgical complications as well as greater risk of bowel, and urinary 
dysfunction (32, 33).  Therefore, the benefits of RP should be considered after taking into account the 
harms associated with the active treatment for prostate cancer. 
Although the clinical evidence suggests that RT (19) or hormone therapy (34) augmented with 
metformin are associated with better clinical outcomes as compared to those without metformin, the 
current study did not find a statistically significant associations between metformin use and the receipt of 
RT or hormone therapy. It is plausible that the choice of initial cancer treatment may be solely determined 
based on age, stage of cancer, and pre-existing chronic conditions and metformin use may not have been 
considered.  The reasons for the positive association between metformin use and RP could not be examined 
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due to the inherent limitations of the claims data analysis. In the future, studies need to be conducted to 
identify the reasons for the higher rates of RP among metformin users as compared to non-users, among 
elderly men with T2DM and incident prostate cancer. 
It should be noted that the current study controlled for the observed selection bias because 
metformin users and non-users were significantly different with respect to their predisposing, enabling, 
need, and external environment characteristics. Without adjustments for the observed selection bias, there 
was not a statistically significant difference in the cancer stage between metformin users and non-users. 
Therefore, accounting for the observed selection bias is important in establishing an association between 
metformin use and the reduction in the risk of advanced prostate cancer diagnosis.  
The current study has a number of strengths. First, the large cohort size and high quality data on 
the clinical and pathological features of cancer at the time of diagnosis enabled us to examine not only the 
association between metformin use and the cancer stage diagnosis but also the initial choice of cancer 
treatment (35). Furthermore, the inclusion of variable on severity of diabetes using a validated method 
enabled to control and relate the effect of severity of disease on the risk of advanced prostate cancer at 
diagnosis and receipt of initial cancer treatment.   
The current study has some limitations as well.  The prescription claims for metformin and other 
drugs were used.  Filling the prescriptions cannot be equated to the actual use of these drugs. The study 
population consisted of elderly men residing in SEER-Regions and enrolled as fee-for-services Medicare 
Beneficiaries, therefore, one cannot generalize the study finding to younger men or all Medicare 
beneficiaries with incident prostate cancer in the US.  Information on many important prognostic factors 
such as body-mass index and smoking could not be adjusted; these factors may be associated with an 
increased risk of advanced prostate cancer diagnosis.  Duration of metformin use could not be adjusted due 
to data limitations. Future studies need to examine whether a greater duration of metformin use is 
associated with a decrease in the risk of advanced prostate cancer at diagnosis.  As the study population 
was restricted to elderly men with T2DM, the current study findings cannot be generalized to men without 
T2DM and incident prostate cancer.   
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3.7 CONCLUSIONS 
Metformin use was associated with a statistically significant reduction in the risk advanced prostate 
cancer diagnosis among elderly men with T2DM and incident prostate cancer. Among elderly men with 
T2DM and incident prostate cancer, RP was more likely among metformin users as compared to non-users.  
No statistically significant associations were observed with regard to metformin use and RT or hormone 
therapy. 
The current study findings highlight the need for additional studies in this area. Other population-
based studies need to be conducted to confirm the study findings.  If confirmed, randomized controlled 
trials can be carried out to examine the causal link between metformin use and the risk of advanced 
prostate cancer diagnosis.  If the findings of the current study are replicated, metformin may be used as a 
preventive therapy to reduce the risk of aggressive prostate cancer among elderly men with T2DM and 
incident prostate cancer.  Future studies should be conducted to evaluate clinical outcomes of metformin 
use among elderly men with prostate cancer and diabetes. 
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Table 3. 1  
Characteristics of the Study Cohort Elderly Medicare Beneficiaries with Diabetes and Incident Prostate 
Cancer by Metformin Use SEER-Medicare-linked Database 2007- 2010 
  Overall Metformin Users Non-Metformin User Sig. 
    N  % N  % N  %   
All   2,652 100             948  35.7          1,704  64.3   
Predisposing Characteristics 
Age at diagnosis, in years       *** 
 66-74          1,579  59.5             609  64.2             970  56.9  
 75+           1,073  40.5             339  35.8             734  43.1  
Race/ethnicity       * 
 Whites          1,914  72.2             680  71.7          1,234  72.4  
 African-American             323  12.2             108  11.4             215  12.6  
 Hispanic/Latino             150  5.7               70  7.4               80  4.7  
 Others             265  10.0               90  9.5             175  10.3  
Marital status        
 Unmarried             222  8.4               73  7.7             149  8.7  
 Married          1,550  58.4             581  61.3             969  56.9  
 Divorced/Separated             393  14.8             136  14.3             257  15.1  
 Others             487  18.4             158  16.7             329  19.3  
Enabling Characteristics 
Quartile of median census 2000 income     * 
 $ 7- $ 34,522             664  25.0             265  28.0             399  23.4  
 $ 34,523-46,224             664  25.0             243  25.6             421  24.7  
 $ 46,229-62,764             664  25.0             229  24.2             435  25.5  
 $ 62,767-200,008             660  24.9             211  22.3             449  26.3  
Quartile of median census 2000 education      
 0 - 8.52             666  25.1             222  23.4             444  26.1  
 8.53-15.16             655  24.7             229  24.2             426  25.0  
 15.17-26.09             664  25.0             248  26.2             416  24.4  
 26.1-100             667  25.2             249  26.3             418  24.5  
PSA Screening        
 Yes          2,415  91.1             872  92.0          1,543  90.6  
 No             237  8.9               76  8.0             161  9.4  
Visit to a PCP        
 Yes          1,858  70.1             672  70.9          1,186  69.6  
 No             794  29.9             276  29.1             518  30.4  
Statin Use       *** 
 Yes          1,576  59.4             656  69.2             920  54.0  
 No          1,076  40.6             292  30.8             784  46.0  
Insulin       *** 
 Yes             102  3.8               62  6.5               40  2.3  
 No          2,550  96.2             886  93.5          1,664  97.7  
External-Environment Characteristics 
SEER-Regions       ** 
 Northeast             487  18.4             146  15.4             341  20.0  
 South             570  21.5             223  23.5             347  20.4  
 North-Central             351  13.2             112  11.8             239  14.0  
 West          1,244  46.9             467  49.3             777  45.6  
      (Continued…) 
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Table 3. 1  
Characteristics of the Study Cohort Elderly Medicare Beneficiaries with Diabetes and Incident Prostate 
Cancer by Metformin Use SEER-Medicare-linked Database 2007- 2010 
  Overall Metformin Users Non-Metformin User Sig. 
    N  % N  % N  %   
Need Characteristics 
DCSI Quartile       ** 
 0 to 0             846  31.9             305  32.2             541  31.7  
 1 to 1             476  17.9             195  20.6             281  16.5  
 2 to 3             811  30.6             297  31.3             514  30.2  
 4 to 13             519  19.6             151  15.9             368  21.6  
                  
Notes: Based on the data of 2,652 elderly men aged 66 years and older diagnosed with prostate cancer between 2008 
and 2009 using a Surveillance, Epidemiology, and End-Results (SEER)-linked Medicare Part D data. Significant 
group differences by metformin use are based on Chi-square tests. % represented in the column are row percentages. 
 
Abbreviations: DCSI: Diabetes Complication Severity Index; PCP: Primary Care Physician; PSA: Prostate Specific 
Antigen; Sig: Level of Significance;  
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Table 3. 2  
Adjusted Odds Ratios and 95% Confidence Intervals from Logistic Regressions On 
Metformin Use among Elderly Medicare Beneficiaries with diabetes Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Data-2007-2010 
  AOR 95% CI Sig. 
Predisposing Characteristics 
Age at Diagnosis    
 66-74 years 1.31 [1.10,1.56] ** 
 75 years or above Ref   
Race/ethnicity    
 Whites Ref   
 African-American 0.91 [0.69,1.21]  
 Latino 1.62 [1.12,2.34] ** 
 Others 0.80 [0.59,1.10]  
Marital status    
 Married Ref   
 Unmarried 0.81 [0.59,1.11]  
 Divorced/Separated 0.94 [0.74,1.20]  
 Others 0.83 [0.66,1.04]  
Enabling Characteristics 
Quartile of median census 2000 income   
 $ 7- $ 34,522 1.72 [1.20,2.46] ** 
 $ 34,523-46,224 1.34 [0.97,1.84]  
 $ 46,229-62,764 1.18 [0.89,1.56]  
 $ 62,767-200,008 Ref   
Quartile of median census 2000 education  
 0 - 8.52 1.24 [0.87,1.77]  
 8.53-15.16 1.21 [0.90,1.62]  
 15.17-26.09 1.18 [0.92,1.51]  
 26.1-100 Ref   
Visit to a PCP    
 Yes 1.12 [0.92,1.35]  
 No Ref   
Statin Use    
 Yes 1.94 [1.63,2.31] *** 
 No Ref   
Insulin    
 Yes 2.95 [1.94,4.49] *** 
 No Ref   
Need-Factors 
DCSI Quartile    
 0 to 1 Ref   
 2 to 2 1.13 [0.89,1.44]  
 3 to 3 0.98 [0.79,1.21]  
 4 to 13 0.65 [0.51,0.84] *** 
External-Environment Characteristics 
SEER-Regions    
 Northeast Ref   
 South 1.40 [1.06,1.85] * 
 North-Central 1.07 [0.78,1.47]  
 West 1.37 [1.08,1.75] * 
     
Notes: Based on the data of 2,652 elderly men aged 66 years and older diagnosed with prostate cancer between 2008 
and 2009 using a Surveillance, Epidemiology, and End-Results (SEER)-linked Medicare Part D data. Significant 
group differences are based on log-likelihood test for metformin use.  
Abbreviations: DCSI: Diabetes Complication Severity Index; PCP: Primary Care Physician; Ref: Reference group; 
Sig: Level of Significance;  
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3. 3  
Number and IPTW-Adjusted Percentage of Men with Localized Versus and Advanced 
Stage of Prostate Cancer by Metformin Use Elderly Medicare Beneficiaries with Diabetes 
and Incident Prostate Cancer Surveillance, Epidemiology and End Results (SEER)-
Medicare Linked Database-2007-2010 
  Localized Advance Sig. 
  N Weighted % N Weighted %  
 Overall 2,493 93.7 159 6.3  
Metformin Use     * 
 Yes 902 95.3 46 4.7  
 No 1,591 93.3 113 6.7  
Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals from 
I (IPTW)  Logistic Regressions 
for Advanced Stage at diagnosis of Cancer 
  Advanced Stage At Diagnosis 
  IPTW 
Unadjusted Odds Ratios and 95% Confidence Intervals 
  OR 95% CI Sig.   
 
Metformin 
 Yes 0.69 [0.49,0.95] *   
 No Ref     
Adjusted Odds Ratios and 95% Confidence Intervals 
 AOR 95% CI    
Metformin      
 Yes 0.68 [0.48,0.97] *   
 No Ref     
              
Notes: Based on the data of 2,652 elderly men aged 66 years and older diagnosed with prostate cancer between 2008 
and 2009 using a Surveillance, Epidemiology, and End-Results (SEER)-linked Medicare data. % are weighted 
percentage for IPTW. Significant difference are based on the log-likelihood test using a logistic regression with IPTW 
weights. Adjusted model controlled for predisposing, enabling, need and external-environment related factors.   
Abbreviations: IPTW: Inverse Probabilities Treatment Weights; PSA: Prostate Specific Antigen Level; PCP; Primary 
Care Physician Visit Sig: Level of Significance; *** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3. 4  
Numbers and IPTW-Adjusted Percentages of the Initial Cancer Treatment Categories 
By Metformin Use Elderly Medicare Beneficiaries with Diabetes and Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database-2007-2010 
  Initial Cancer Treatment 
  RP RT Hormone only None Sig. 
  N Wt % N Wt % N Wt 
% 
N Wt. %  
 All 503 17.4 1,273 46.5 214 8.6 662 27.6  
Metformin Use        ** 
 Yes 211 21.3 457 46.6 71 8.6 209 23.8  
 No 292 16.3 816 46.4 143 8.7 453 28.5  
Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals (CI) from 
IPTW-adjusted Multinomial  Logistic Regressions on Initial Cancer Treatment 
(Reference Group = No Cancer Treatment)  
 
Unadjusted Odds Ratios and 95% Confidence Intervals 
  RP RT Hormone Therapy 
  OR 95% CI Sig. OR 95% CI Sig. OR 95% CI Sig. 
Metformin Use 
 
        
 Yes 1.54 [1.24,1.92] *** 1.20 [1.04,1.44]  1.18 [0.89,1.56]  
 No Ref   Ref   Ref   
           
Adjusted Odds Ratios and 95% Confidence Intervals (CI) 
  RP RT Hormone Therapy 
  AOR 95% CI Sig. AOR 95% CI Sig. AOR 95% CI Sig. 
Metformin         
 Yes 1.45 [1.14,1.86] ** 1.08 [0.89,1.32]  1.15 [0.85,1.56]  
 No Ref   Ref   Ref   
                      
 
Notes: Based on the data of 2,652 elderly men aged 66 years and older diagnosed with prostate cancer between 2008 
and 2009 using a Surveillance, Epidemiology, and End-Results (SEER)-linked Medicare Part D data. Significant 
group differences by metformin use are based on Chi-square tests. % represented in the column are weighted 
percentages. Adjusted model controlled for predisposing, enabling, need and external-environment related factors.   
Abbreviations: IPTW: Inverse-Probability Treatment Weights; RP: Radical Prostatectomy; RT: Radiation Therapy; 
Sig: Level of Significance, Wt:  Weighted percentage. 
 





































Elderly Men diagnosed with prostate cancer as primary cancer at age 
66 years and above, malignant tumor, alive at the time of diagnosis and 
diagnosed between 2002 and 2009  
With 13-month continuous eligibility in Medicare Part A and Part B 
and No HMO enrollment during 1 year before diagnosis  
N = 2,652 
 
Reasons for exclusion: 
 Men with carcinoma in-situ (N =17) 
 Men diagnosed with prostate cancer 
at age 65 or below  (N =19,523) 
 Invalid death status (N =1,870)  
 
Men with prostate cancer identified using SEER site recode: 54 and 
ICD-10-Code: C61.9) between 2008 and 2009 
N =74,791 
Men diagnosed with prostate cancer as a primary cancer and alive at 
the time of diagnosis  
N = 67,028 
Reason for exclusion:  
 Men diagnosed with prostate cancer at 
the time of death or autopsy (N= 644) 
 Men with multiple cancers   
(N =7,119) 
Elderly men diagnosed with prostate cancer as primary cancer, and alive 
at the time of diagnosis between 2008 and 2008 
N = 45,618 
 No Part A and B enrollment or HMO 
enrollment (N =18,790) 
 No Part D enrollment (N = 18,386) 
 
Elderly Men diagnosed with prostate cancer as primary cancer at age 66 
years  and above, malignant tumor, alive at the time of diagnosis and 
diagnosed between 2002 to 2009  
N = 8,442 
Reasons for exclusion: 
 No History of Diabetes (N =5,685) 
 
Appendix 3. 1 Study Cohort Development Flow diagram for Study Population of Elderly Medicare Beneficiaries 
diagnosed with Prostate Cancer and Diabetes 
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Appendix 3. 2  
Codes and Algorithms to Identify Diabetes Severity Diabetes Complication Severity Index (DCSI)  
developed by Young et al. and modified by Chang et al. 
 Complications ICD-9 CM Code DCSI Score 
Retinopathy   
 Diabetic ophthalmologic disease 250.5x 1 
 Background retinopathy 362.01 1 
 Other retinopathy 362.1 1 
 Retinal edema 362.83 1 
 CSME 362.53 1 
 Other rerinal disorders 362.81, 362.82 1 
 Proliferative retinopathy 362.02 2 
 Retinal detachment 361.xx 2 
 Blindness 369.xx.00-.99 2 
 Vitreous hemorrhage 379.23 2 
Nephropathy   
 Diabetic nephropathy 250.4 1 
 Acute glomerulonephritis 580 1 
 Nephrotic syndrome 581 1 
 Hypertension, nephrosis 581.81 1 
 Chronic glomerulonephritis 582 1 
 Nephritis/nephropathy 583 1 
 Chronic renal failure 585  
 Renal failure NOS 586  
 Renal insufficiency 593.9  
Neuropathy   
 Diabetic nephropathy 356.9, 250.6 1 
 Amyotrophy 358.1 1 
 Cranial nerve palsy 951.0, 951.1, 951.3 1 
 Mononeuropathy 354.0-355.9 1 
 Charcot’s arthopathy 713.5 1 
 Polyneuropathy 357.2 1 
Cerebrovascular   
 TIA 435 1 
 Stroke 431, 433, 434, 436 2 
Cardiovascular   
 Atherosclerosis 440.xx 1 
 Other IHD 411 1 
 Angina pectoris 413 1 
 Other chronic IHD 414 1 
 Myocardial infarction 410 2 
(Continued..) 
 Ventricular fibrillation, arrest 427.1, 427.3 2 
 Atrial fibrillation, arrest 427.4, 427.5 2 
 Other ASCVD 429.2 1 
 Old myocardial infarction 412 2 
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Appendix 3. 2  
Codes and Algorithms to Identify Diabetes Severity Diabetes Complication Severity Index (DCSI)  
developed by Young et al. and modified by Chang et al. 
 Complications ICD-9 CM Code DCSI Score 
 Heart failure 428 2 
 Atherosclerosis, severe 440.23, 440.24 2 
 Aortic aneurysm/dissection 441 2 
Peripheral vascular disease   
 Diabetic PVD 250.7 1 
 Other aneurysm, LE 442.3 1 
 PVD 443.81, 443.9 1 
 Foot would + complication 892.1 1 
 Claudication, intermittent 443.9 1 
 Embolism/thrombosis (LE) 444.22 2 
 Gangrene 785.4 2 
 Gas gangrene 0.4 2 
 Ulcer of lower limbs 707.1 2 
Metabolic   
 Ketoacidosis 250.1 2 
 Hyperosmolar 250.2 2 
 Other coma 250.3 1 
    
Note: The table is adapted from the previous algorithm defined by Young et al. and modified by Change et al. to 
identify the severity of diabetes using claims database.  Severity index was based on a scale ranging from 0 to 2 for 
each complication as follows: 0 = no abnormality, 1 = some abnormality, 2 = severe abnormality.   
 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CSME, cystoid macular edema/degeneration; DCSI, 
Diabetes Complications Severity Index; IHD, ischemic heart disease; ICD-9-CM, International Classification of 
Diseases, Ninth Revision, Clinical Modification; LE, lower extremity; NOS, not otherwise specified; PVD, peripheral 
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Chapter 4 
Impact of Prostate Cancer Diagnosis on Non-Cancer Hospitalizations by Types of Chronic 
Conditions among Elderly Medicare Beneficiaries with Incident Prostate Cancer 
 
4.1 ABSTRACT 
OBJECTIVES: To analyze the impact of cancer diagnosis on non-cancer hospitalizations by comparing 
them between the pre- and post-cancer period in a cohort of fee-for-service Medicare beneficiaries with 
incident prostate cancer.  The study additionally examined the impact of cancer diagnosis on non-cancer 
hospitalizations by the types of pre-existing chronic conditions, after controlling for the predisposing, 
enabling, need, and external environment factors.  
METHODS: A population-based retrospective cohort study was conducted using the Surveillance, 
Epidemiology and End-Results (SEER) -Medicare linked database for the years 2000 to 2010.  The study 
cohort consisted of 57,489 elderly men (≥ 67 years) with incident prostate cancer.  Non-cancer 
hospitalizations were identified in six time periods (t1-t6) before and after the incidence of prostate cancer. 
Each time period consisted of 120 days. Time periods 1, 2, and 3 represented the pre-cancer period, and 
time periods 4, 5, and 6 represented the post-cancer period. For each time period, non-cancer 
hospitalizations were defined as inpatient admissions with primary diagnosis codes not related to prostate 
cancer.  
The types of chronic conditions were grouped into the following seven mutually exclusive 
categories: (1) only cardio-metabolic conditions; (2) only mental health conditions; (3) only respiratory 
conditions; (4) cardio-metabolic and mental health conditions; (5) cardio-metabolic and respiratory 
conditions; (6) all three-cardio-metabolic, mental health, and respiratory conditions, and 7) none of the 
three types of chronic conditions.  Individuals who were diagnosed with new chronic conditions during the 
pre- and post-cancer periods were excluded. Selection of other independent variables was based on the 
ABM model and consisted of the predisposing (age, race/ethnicity, and marital status), enabling (income, 
education, cancer-treatment, and primary care visit), need (number of other chronic conditions), and 
external environment (region, number of oncology and urology unit in a county) factors. 
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Bivariate and multivariate comparisons of the rates of non-cancer hospitalizations between the pre- 
and post-cancer period accounted for repeated measures design. Multivariable regressions were performed 
using the generalized estimating equation (GEE) technique with logit link function. The extent to which the 
pre- and post-cancer period non-cancer hospitalizations differed by the types of chronic conditions, after 
controlling for other independent variables, are reported in terms of the estimated probabilities from the 
GEE models.   
RESULTS:  The rate of non-cancer hospitalizations during the post-cancer period was higher as compared 
to the pre-cancer period.  For example, the rates were 9.2% during the post-cancer period, t4 (i.e. 120 days 
immediately after the diagnosis of incident cancer) and 3.8% during the pre-cancer period, an increase of 
5.4 percentage points. After accounting for correlations due to repeated measures and unadjusted model, 
elderly men were 77% more likely to have any non-cancer hospitalizations during the post-cancer period as 
compared to the pre-cancer period (Odds Ratio, OR: 1.77, 95% Confidence Interval, CI: 1.71, 1.82). After 
adjusting for predisposing, enabling, need and external-environment-related factors, elderly men were 80% 
more likely to have non-cancer hospitalizations during the post-cancer period as compared to pre-cancer 
period (Adjusted OR, AOR: 1.80, 95% CI: 1.75, 1.86).   
For all categories of chronic conditions, the rates of non-cancer related hospitalizations were 
higher during the post-cancer period as compared to the pre-cancer period. For example, among elderly 
men with all the three types of chronic conditions, the rates were 26.5% during the post-cancer period (t4) 
and 15.1% during the pre-cancer period (t1), an increase of 11.4 percentage points. Among elderly men 
with none of the chronic conditions, the rates were 5.8% during the post-cancer period (t4) and 1.4%during 
the pre-cancer period (t1), an increase of 4.4 percentage points.  . After adjusting for correlations due to 
repeated measures, elderly men with all the three types of chronic conditions had the greatest increase in 
the rates of non-cancer hospitalizations during the post-cancer period as compared to the pre-cancer period.  
Elderly men with none of the three types of chronic conditions had the lowest increase in the rates of non-
cancer hospitalizations in the post-cancer period as compared to the pre-cancer period.   
CONCLUSIONS:  Elderly men with prostate cancer had a significant increase in the risk of non-cancer 
hospitalizations after the diagnosis of prostate cancer.  For all chronic condition categories, there was an 
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increase in non-cancer hospitalizations during the post-cancer period as compared to the pre-cancer period. 
Elderly men with all the three types of chronic conditions had the greatest increase in non-cancer 
hospitalizations compared to all other chronic condition categories. 
IMPLICATIONS:  The study findings highlight the negative impact of cancer diagnosis on the risk for 
non-cancer hospitalizations among men with prostate cancer pre-existing chronic conditions.  The risk for 
non-cancer hospitalizations was the highest among those with pre-existing chronic conditions that span 
multiple organ systems. Future studies need to evaluate whether appropriate management of the pre-
existing conditions can reduce the risk of non-cancer hospitalization during the post-cancer period.   
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4.2 INTRODUCTION 
The period immediately following a cancer diagnosis can be considered as a period of turbulence 
for the management of pre-existing chronic conditions. As pointed out by Piette et al., cancer is often 
considered as a dominant condition that eclipses the management of all other chronic conditions (1).  It has 
been reported that among individuals with cancer, the management of conditions that are not related to 
cancer may be neglected (2).  Undermining the management of chronic conditions among individuals with 
any cancer may result in adverse outcomes and poor quality of care for non-cancer related conditions.  One 
study among elderly men with prostate cancer found that men with prostate cancer received poor-quality of 
non-cancer management (3).  However, this study did not examine the relationship between non-cancer 
related hospitalizations and pre-existing chronic conditions.  
It is important to examine hospitalizations among elderly men with prostate cancer as they indicate 
a worsening of existing conditions to the point of requiring immediate attention for monitoring and 
management in an inpatient environment. In addition, hospitalizations have been associated with 
significant mortality and healthcare costs (4).  In 2012, $892.4 billion was spent on hospitalizations in the 
US and hospitalization expenditures were expected to increase by 5% every year (5). Therefore, the rate of 
non-cancer hospitalizations among the elderly with prostate cancer not only reflect the hospitalizations for 
non-cancer related conditions, but also reflect enormous financial burden to the US healthcare system.  
Among men of all ages with prostate cancer, many hospitalizations are attributable to chronic 
conditions other than prostate cancer.  For example, using the encounter-level data for the years 1997 
through 2004, Milenkovic et al. found that among adults with prostate cancer, 84% of the inpatient 
encounters were for chronic conditions other than prostate cancer (6). An overwhelming majority of these 
inpatient encounters (90%) was observed among elderly men aged 65 years or older. However, the study 
investigators did not provide any information on the impact of cancer diagnosis on non-cancer 
hospitalizations.  Furthermore, the study used encounter-level data rather than patient-level data ignoring 
multiple hospitalizations by the same individual. Thus, the impact of prostate cancer diagnosis on the 
hospitalizations due to conditions other than cancer remains unknown. 
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 The initial treatment of prostate cancer may also increase the risk of hospitalizations among 
elderly men with prostate cancer.  Many observational studies have shown a positive association between 
use of androgen deprivation therapy (ADT) or radiation therapy (RT) and hospitalizations for cardio-
metabolic conditions among men with prostate cancer (7-9), (10).  However, these studies included a 
population with established prostate cancer and examined the risk of hospitalizations only for specific non-
cancer hospitalizations. Furthermore, these studies did not investigate the association between cancer 
diagnosis and non-cancer hospitalizations. 
It is important to analyze the association between cancer diagnosis and the risk for non-cancer 
hospitalizations by types of chronic conditions. Elderly men with prostate cancer have differential rates of 
chronic conditions. For example, cardio-metabolic conditions (example: heart disease and diabetes) are 
observed in 18.1% of men with prostate cancer, followed by respiratory conditions (example: chronic 
obstructive pulmonary disease-9.8%) (11) and mental health conditions (example: depression-8%) (12).  
Thus, the risk for hospitalizations may differ by the types of chronic conditions. One study, not specific to 
prostate cancer, reported that individuals with cardio-metabolic conditions had higher rates of annual 
hospitalizations (40%) as compared to those with respiratory conditions (20%) among adults aged 50 years 
and older in the US (13). The incidence of prostate cancer can have varying impact on the risk for non-
cancer hospitalizations among men different types of pre-existing chronic conditions. Therefore, it is 
important to analyze the impact of cancer diagnosis on the risk of non-cancer hospitalizations by the types 
of pre-existing chronic conditions among elderly men diagnosed with prostate cancer. 
 An understanding of the risk of non-cancer hospitalization risk after the diagnosis of cancer for 
those with incident prostate cancer can inform surveillance efforts and the management of chronic 
conditions among elderly men with prostate cancer. Therefore, the primary objectives of the current study 
are to analyze the impact of cancer diagnosis on non-cancer hospitalizations among elderly men with 
incident prostate cancer and examine whether the impact of cancer diagnosis on non-cancer 
hospitalizations differs by the types of chronic conditions.  
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4.3 CONCEPTUAL FRAMEWORK 
 The conceptual framework was based the ABM model, described in Chapter 1.  The independent 









4.4.1 Study Design  
 A retrospective longitudinal cohort design with baseline, pre and post-cancer periods was used. 
Using the date of cancer diagnosis as the index date, a 24-month window before the index date was 
constructed. This 24-month period was split into two 12-month periods (i.e. the baseline and pre-cancer 
period). This was necessary because identification of pre-existing chronic conditions and non-cancer 
hospitalizations during the pre-cancer period involved the use of inpatient claims. To avoid circular 
reasoning, the first 12-month period was used as the baseline period, during which the types of chronic 
conditions and other independent variables were measured.  The 12-month period before the diagnosis of 
cancer was considered as the pre-cancer period and this period was used to derive non-cancer 
hospitalizations. The post-cancer period consisted of 12 months after the diagnosis of cancer.  However, to 
ensure a robust study design, the non-cancer hospitalizations were measured repeatedly every 120 days 
during the pre- and post-cancer period, yielding a total 6 repeated measures per individual.  Thus, t1, t2, t3 
represented the pre-cancer period and t4, t5, and t6 represented the post-cancer period.  The graphical 
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Figure 4. 1 Study Theoretical Framework: Adaptation of Andersen Behavioral Model for Aim 3 
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4.4.2 Data Sources 
The current study utilized the SEER-Medicare linked database with prostate cancer cases 
diagnosed between 2002 and 2009 and their linked claims between 2000 and 2010.  Please see Chapter 1 
for details.   
4.4.3 Study Cohort 
The study population was based on 289,701 men diagnosed with incident prostate cancer between 
January 1st 2002 and December 31st 2009. Men with multiple cancers (N =25, 785); diagnosed with 
prostate cancer during the autopsy (N = 2,944); men younger than 67 years of age and died during the 
study period (N = 111,643) were excluded. The cohort was further restricted to those with continuous fee-
for-service Medicare Part A and Part B enrollment during the entire study period (N = 101,302).  To reduce 
misclassification bias, individuals with newly diagnosed conditions during the pre-cancer and post-cancer 
periods (N = 40,544) were excluded.  After excluding individuals with missing information on 
race/ethnicity, county, and in-situ, unknown, and advanced cancer stage, the final study cohort comprised 
of 57,589 elderly men with incident prostate cancer. Appendix 4.1 provides details of the study cohort 
development.  
4.4.4 Key Dependent Variable: Non-cancer hospitalizations 
Inpatient admissions during the pre- and post-cancer periods were derived from the MEDPAR file. 
Non-cancer hospitalization was defined as any admission to an inpatient facility with a principal diagnosis 
for conditions other than prostate cancer. Hospitalizations with the primary diagnosis of prostate cancer 
t1 t2 t3 t4 
Post-Cancer Period: 
12 months after diagnosis of Cancer 
Jan 2002-Dec 2010 
Baseline Period - Identification of 
chronic conditions 12 months before 
pre-cancer period 
 
Index date – Cancer Diagnosis Date 
(2002-2009) 
Pre-Cancer Period: 
12 months before diagnosis of Cancer 
t5 t6 
Figure 4. 2 Study Design for Aim 3 
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(ICD-9 CM codes - 185, 233.4, or V1046) were considered as prostate-cancer-related hospitalizations and 
were excluded from the analysis (6). This approach is commonly used in published studies to identify 
disease-specific hospitalizations (4, 14).  
However, the challenges in measuring non-cancer hospitalizations should also be noted. Elderly 
men with prostate cancer may have hospitalizations due to cancer-related complications such as bowel, 
sexual or urinary dysfunction or cancer-related procedures such as surgery. Therefore, a sensitivity analysis 
was carried out by excluding hospitalizations for cancer-related complications or primary or secondary 
procedure codes for cancer-related procedures.  As the findings remained consistent between the two 
definitions, only the results from the primary analyses are reported. 
4.4.5 Key Independent Variable: Types of co-occurring chronic condition (One of the need factors) 
We classified the common types of chronic conditions using the organ domains (15).  We selected 
this approach because of the synergism in treatment and self-management approaches. For example, the 
management of cardio-metabolic conditions such as diabetes and heart disease have similar treatment and 
self-management strategies. Among men with prostate cancer, cardio-metabolic diseases (diabetes and 
heart disease), respiratory diseases (COPD and asthma), and mental health conditions (depression and 
other mental conditions) are common.  These common chronic conditions were classified into seven 
mutually exclusive categories: (1) cardio-metabolic conditions only; (2) mental health conditions only; (3) 
respiratory conditions only; (4) cardio-metabolic and mental health conditions; (5) cardio-metabolic and 
respiratory conditions; (6) having all the three types of chronic conditions; and 7) having none of the three 
types of chronic conditions. Due to insufficient numbers for the category “respiratory and mental health 
conditions”, this category was excluded from analysis.  All the chronic conditions were identified during 
the baseline period using one inpatient claim or two outpatient claims for each of the chronic conditions. 
4.4.6 Other Independent Variables  
4.4.6.1 Predisposing Characteristics 
Age, race/ethnicity, and marital status were the predisposing characteristics. Age at the time of 
diagnosis (67 to 74 years, 75 and above years), race/ethnicity (White, African American, Hispanic, and 
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other), and marital status (married, divorced/separated, unmarried, and others) were identified from the 
PEDSF file.   
4.4.6.2 Enabling Characteristics   
 Income, education, access to care and the initial cancer treatment were the enabling factors. The 
PEDSF file provides 2000 census-tract level information as education level and median income. For our 
population, we created quartiles of census tract education levels and median income. Access to care was 
defined using proxy measures in the absence of any direct measures for the same. The proxy measure for 
access to care was measure with at least one visit to a primary care provider during the baseline period 
(16). 
Receipt of active treatment was identified using inpatient, outpatient and carrier files with 
appropriate ICD-9 CM diagnostic and procedure codes, CPT or HCPCS codes or Revenue Center code 
during the six months after the index date (Appendix 2.2).  Based on previously validated codes, active 
treatment was either the receipt of radiation, surgery, or hormonal therapy (17, 18).  Use of the 
combination of Luteinizing Hormone Releasing hormone (LHRH) agonist and an anti-androgen during the 
fourth time period after diagnosis of prostate cancer from inpatient or outpatient or carrier file was labeled 
as hormone therapy (19).  Men who did not have any of the above-mentioned treatment categories were 
classified as having no cancer treatment. We classified the cancer treatment into four groups based on a 
hierarchy: 1) Radical Prostatectomy (RP); 2) Radiation Therapy (RT); 3) Hormone Therapy; and 4) None 
of the RP, RT or hormone therapy. 
4.4.6.3 External environment characteristics 
 External environment characteristics comprised of the individual’s region (Northeast, South, 
North-Central, and West) and county-level healthcare resources such number of radiation-oncology units 
and urology units. (20).  County-level healthcare resources were captured by the number of radiation 
oncology units and urology units were derived from the AHRF. The description of the AHRF file can be 
found in chapter 1 in method section.  
  
                                                                                                    
Page | 84  
 
Need Characteristics:  
  A very small percentage of men (<5%) had chronic conditions other than the cardio-metabolic, 
mental-health, and respiratory conditions. Forty-two other conditions were derived using the list of chronic 
conditions from published literature (1).  We calculated the total number of other chronic conditions during 
the baseline period and categorized as “zero or one condition” and “two or more conditions”. 
The American Joint Committee on Cancer (AJCC) Tumor-Node-Metastases (TNM) stage 
classifications was utilized for staging of prostate cancer.  The cohort was restricted to elderly men with 
no-node positive or non-metastatic prostate cancer. Three groups of cancer stage at diagnosis were created 
as: 1) T1 or less; 2) T2 and 3) T3 or T4.   
4.5 STATISTICAL ANALYSES 
As the non-cancer hospitalizations were measured repeatedly during each of the six-time periods, 
the observations are no longer independent and are correlated. The use of standard methods may lead to 
erroneous variance estimates because these methods assume “independence of observations”. Therefore, 
both the bivariate and multivariate comparisons of the rates of non-cancer hospitalizations between the pre-
and post-cancer period accounted for correlations due to the repeated measures design. 
There are many multivariable methods to account for correlations due to repeated measures. One 
such model is suggested by Liang et al (21).  This method involves the use of the generalized estimating 
equations (GEE) with specific the correlation-matrix.  The general form of the model is given in the 




) = 𝛽0 +  𝛽1 (𝑡𝑖𝑚𝑒𝑖𝑗) +  𝛽2 (𝐶𝐶)𝑖 + ⋯ +  𝛽𝑛 (𝑁𝑡ℎ 𝑉𝑎𝑟𝑖𝑎𝑏𝑙𝑒) 𝑖  
where pij denotes the probability of non-cancer hospitalizations for individual i, in time period j. 
Timeij denotes a specific time period j (pre- or post-cancer period) for an individual, i. CCi denotes 
presence of particular types of chronic conditions at baseline period for an individual, i. The model also 
included other independent variables such as predisposing, enabling, need and external-environment 
characteristics measured for an individual, i.   𝛽s are the regression coefficients to be estimated.  As can be 
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seen from the equation, except for the pre- and post-cancer time periods, none of the other independent 
variables varied over time and were considered fixed effects.   
The GEE approach developed by Liang and Zeger specifies three types of correlation structures - 
exchangeable, autoregressive, and unstructured –to control for correlations between repeated observations. 
Exchangeable correlation structure, the most commonly used, assumes that every pair of residuals for a 
subject have the same correlation. i.e. the same correlation between pairs (t1, t3) and (t4, t6) for every 
individual.  The autoregressive correlation structure depends on the time separating two repeated events for 
the same individual. In other words, the correlation for the non-cancer hospitalizations pair (t1, t2) may be 
greater than that of the pair (t1 , t4).  In the unstructured correlation structure, the correlations between the 
particular pairs of time periods can be different than any other pairs of time periods.  As the parameter 
estimates of the association between non-cancer hospitalization and types of chronic conditions remained 
the same under different correlation structures (i.e. autoregressive and unstructured), only the results from 
GEE models with exchangeable correlation structure are reported.  The overall model fit was examined by 
the quasi-likelihood information criterion (qIC) (22).  
For ease of interpretation, the predicted probabilities of non-cancer hospitalizations between the 
pre-and post-cancer period were compared.  These probabilities were calculated using the parameter 
estimates from the GEE models, assuming an additive effect (23).  Statistical analyses using GEE models 
were carried out in STATA version 13. (StataCorp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP.)  The predicted probabilities were derived using the “margins” command in 
STATA-13. 
It should be noted that in the current study, the term “risk” is often used to describe the results 
associated with odds ratios (OR). Although the risk ratio and OR will yield different estimates,  for events 
with low prevalence (≤ 10%) (24) such as non-cancer hospitalizations, these two measures will produce 
similar results.   
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4.6 RESULTS  
4.6.1 Study Population  
The study cohort (N = 57,489) were primarily whites (82.4%), in the age group 67-74 years (58.3%, mean 
age = 74.6 years, standard deviation = 5.1), and married (68.5%).   Most men in the study cohort received 
treatment for cancer (80.5%). (see Table 4.1).  
4.6.2 Non-cancer-Hospitalizations during the pre- and post-cancer period 
 Table 4.2 reports the rates of non-cancer-hospitalizations during each of the time periods.  The 
rates of non-cancer-hospitalizations were the highest during the post-cancer period (t4, i.e., 120 days 
immediately after the cancer diagnosis) and lowest during the pre-cancer period (t2) (9.2% vs 3.4%), an 
increase of 5.8 percentage points.   
Table 4.2 also shows the rates of non-cancer hospitalizations by the types of chronic conditions.  
Of all the categories of chronic conditions, the rates of non-cancer hospitalizations during the post-cancer 
were significantly higher compared to the pre-cancer period. Among elderly men with all three types of 
chronic conditions, the rates were 26.5% during the post-cancer period (t4) and 15.1% during the pre-
cancer period (t4), an increase of 11.4 percentage points. Among elderly men with none of the chronic 
conditions, the rates were 5.8% during the post-cancer period (t4) and 1.4% during the pre-cancer period 
(t1), an increase of 4.4 percentage points. Similar increases were seen for other chronic condition 
categories.  
Table 4.3 displays the ORs and AORs and 95% confidence intervals (CI) using the unadjusted 
(Model I) and adjusted GEE models (Models II and III) for non-cancer hospitalizations with exchangeable 
correlation structures. After accounting for the correlations due to repeated measures, model I revealed that 
elderly men were 77% more likely to have non-cancer hospitalizations during the post-cancer period as 
compared to pre-cancer period (OR: 1.77, 95% CI: 1.71, 1.82).  In model II, with adjustments for only the 
types of chronic conditions, elderly men were 79% more likely to have non-cancer hospitalizations during 
post-cancer period (AOR: 1.79, 95% CI: 1.73, 1.84) as compared to the pre-cancer period., In model III, 
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which controlled for all the independent variables, elderly men were 80% more likely to have non-cancer 
hospitalizations during the post-cancer period as compared to the pre-cancer period. 
4.6.3 Probabilities of Non-cancer hospitalizations by Pre and Post-Cancer Period 
Table 4.4 displays the probabilities of non-cancer hospitalizations by the pre-and post-cancer 
period for the types of chronic conditions.  Based on the fully adjusted model (Model III), an increase in 
the probability of non-cancer hospitalizations was observed for the post cancer period (p = 0.028) as 
compared to pre-cancer period (probabilities, p: 0.028 vs. 0.050, change in p = .022).  
Elderly men with all the three types of chronic conditions had the greatest increase in the 
probabilities of non-cancer hospitalizations during post cancer period (p: 0.121) as compared to pre-cancer 
period (p: 0.159), whereas, elderly men with none of the types of chronic conditions had the lowest change 
in the probabilities of non-cancer hospitalizations (p: 0.021) during post-cancer period as compared to pre-
cancer period (p: 0.028). With regard to other chronic condition categories, those with cardio-metabolic 
conditions alone,  those with cardio-metabolic and respiratory conditions, those with cardio-metabolic and 
mental-health conditions had higher risk of non-cancer hospitalizations during the post-cancer period and 
pre-cancer period (0.046 vs 0.061, 0.073 vs 0.097, 0.067 vs 0.090), respectively.  
4.7 DISCUSSION 
The current study analyzed the impact of prostate cancer diagnosis on the risk of non-cancer 
hospitalizations among elderly fee-for-service Medicare beneficiaries with localized incident prostate 
cancer between 2002 and 2009 using the SEER-Medicare linked database. Till date, the current study is the 
largest population-based cohort that has examined the risk of non-cancer hospitalizations before and after a 
diagnosis of prostate cancer among elderly men with incident prostate cancer. We observed many 
noteworthy findings, which have implications for a better management of pre-existing chronic conditions 
among men with incident prostate cancer.  
Elderly men with an incident prostate cancer had a higher risk of non-cancer hospitalization during 
the post-cancer period as compared to the pre-cancer period, after controlling for a comprehensive list of 
risk factors. A closer examination of the rates of hospitalizations over six time periods suggested that the 
                                                                                                    
Page | 88  
 
highest rates of non-cancer hospitalizations occurred during first four months after the cancer diagnosis. 
There are several plausible explanations for this increased risk. It has been documented that the diagnosis 
of prostate cancer, by itself, can trigger psychological distress, anxiety and suicidal ideations (39). The 
increase in the psychological stress may increase the blood levels of epinephrine and norepinephrine 
resulting in increased heart rate, blood pressure and levels of blood sugars. In fact, studies have shown that 
acute psychological stress may lead to stimulate inflammatory markers such as interleukins, sex hormones 
and cortisol levels, which may precipitate into serious conditions such as heart disease (25).  Another 
plausible explanation is that a diagnosis of cancer may eclipse the management of all other chronic 
conditions and patient care may be centered on cancer treatment and recovery from cancer.  
Upon closer examination of our study findings by types of chronic conditions, we found that those 
with cardio-metabolic conditions alone or combinations of cardio-metabolic conditions with respiratory or 
mental health conditions had a greater increase in the risk of non-cancer hospitalizations during the post-
cancer period as compared to the pre-cancer period. Previous literature suggests that elderly men with pre-
existing cardio-metabolic conditions may experience acute emotional or psychological stress, which may 
lead to greater incidence of cardiovascular events (26, 27), which in turn may lead to increased 
hospitalizations. It has to be noted that the current study did not include newly-diagnosed chronic 
conditions, therefore, increased hospitalizations during the post-cancer period for this group may suggest 
the worsening of pre-existing cardio-metabolic conditions due to prostate cancer diagnosis.   
The study findings reinforce the need for more research on management of non-cancer conditions 
before and after diagnosis of cancer and its effect on the non-cancer hospitalizations among elderly men 
with pre-existing chronic conditions, Special attention needs to be paid to chronic disease care given during 
the period immediately following the cancer diagnosis. As elderly men with cardio-metabolic conditions 
are most vulnerable to increased hospitalizations, research, program, policy, and intervention efforts need 
to focus on reducing the excess non-cancer hospitalizations in this group.  
 The study findings have a key methodological implication for estimating cancer-related healthcare 
utilization. Typically, cancer-related annual utilization among men with prostate cancer is estimated by 
subtracting the total utilization during the year before cancer diagnosis from the total utilization after in a 
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year after cancer diagnosis with an assumption of no change of non-cancer related utilizations during pre-
and post-cancer period (28-32).  The current study findings revealed a greater risk of non-cancer 
hospitalizations during the year after as compared to the year before the diagnosis of prostate cancer.  
Therefore, the standard methods of calculating cancer-related utilization may overestimate the cancer-
related utilizations. 
Our study has many advantages. The current study is one of the very few studies to explore the 
trajectory of non-cancer outcomes (i.e. hospitalizations) during the pre-cancer and post-cancer period 
among fee-for-service Medicare beneficiaries with incident localized prostate cancer. To the best of our 
knowledge, this study is the largest population-based study, which used a comprehensive list of factors 
using the cancer registry-linked administrative claims data.  This study used a robust repeated measures 
study design.  The pre-existing chronic conditions were classified using a conceptual framework adopted 
by the Department of Health and Human Services (DHHS) for research, program, and policy perspectives.   
However, the current study findings need to be interpreted in the context of its limitations. 
Although, due diligence was given in measuring non-cancer hospitalizations based on previously published 
studies, one cannot rule out the possibility that some non-cancer hospitalizations may be due to cancer 
treatment or cancer-related complications. For example, cancer surgery may have led to complications such 
as the sepsis or other infections, which were considered as non-cancer hospitalizations in the current study. 
Despite having a large cohort, cell sizes for some chronic conditions were too small to be included in the 
analyses.   
Furthermore, an observational study design was used, which has its own limitations. The study 
population was restricted to elderly men enrolled in fee-for-service Medicare services only residing in the 
SEER-regions, therefore, we cannot generalize the study findings to all elderly Medicare beneficiaries with 
prostate cancer. Although we controlled for a comprehensive list of variables to examine multivariable 
associations between the risk of non-cancer hospitalizations and incidence of prostate cancer, we were not 
able to control for other risk factors such as the body-mass index, physical activity, and smoking, which 
may be associated with greater risk of non-cancer hospitalizations among elderly men with prostate cancer. 
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4.8 CONCLUSION 
Diagnosis of incident prostate cancer was associated with an increase in the risk of non-cancer 
hospitalizations among elderly men with incident localized prostate cancer. Specifically, those with cardio-
metabolic conditions only or those with cardio-metabolic conditions and mental health or respiratory 
conditions had a higher increase in the risk of non-cancer hospitalizations during the post-cancer period as 
compared to the pre-cancer period. Future research needs to examine whether better management strategies 
for cardio-metabolic and other chronic conditions can reduce the increased risk for non-cancer 
hospitalizations after a diagnosis of prostate cancer.    
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Table 4. 1  
Characteristics of Elderly Medicare Beneficiaries with Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)- 
Medicare Linked Database 2000 – 2010 
    N  % 
All  57,489 100 
Types of Chronic Conditions          
 CM only         21,712  37.8 
 MH Only              813  1.4 
 RSP only           2,277  4.0 
 CM + MH           1,148  2.0 
 CM + RSP           5,114  8.9 
 None         25,811  44.9 
 All Three              614  1.1 
Predisposing Characteristics 
Age at diagnosis, in years   
 66-74         33,495  58.3 
 75+          23,994  41.7 
Race/ethnicity   
 Whites         47,384  82.4 
 African-American           6,272  10.9 
 Hispanic/Latino           1,011  1.8 
 Others           2,822  4.9 
Marital status   
 Unmarried           3,654  6.4 
 Married         39,386  68.5 
 Divorced/Separated           6,993  12.2 
 Others           7,456  13.0 
Enabling Characteristics 
Quartile of median census 2000 income   
 $ 7- $ 34,522         14,362  25.0 
 $ 34,523-46,224         14,368  25.0 
 $ 46,229-62,764         14,369  25.0 
 $ 62,767-200,008         14,390  25.0 
Quartile of median census 2000 education  
 0 - 8.52         14,371  25.0 
 8.53-15.16         14,376  25.0 
 15.17-26.09         14,373  25.0 
 26.1-100         14,369  25.0 
Visit to a PCP   
 Yes         37,405  65.1 
 No         20,084  34.9 
Active Treatment   
 RP          11,520  20.0 
 RT          29,234  50.9 
 Hormone Therapy            5,510  9.6 
 No Treatment          11,225  19.5 
External-Environment Characteristics 
SEER-Regions   
 Northeast         11,360  19.8 
 South         14,095  24.5 
 North-Central           7,288  12.7 
 West         24,746  43.0 
  (Continued…) 
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Table 4. 1  
Characteristics of Elderly Medicare Beneficiaries with Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)- 
Medicare Linked Database 2000 – 2010 
    N  % 
Quartile of Radiation Oncology    
 0 to 1         15,127  26.3 
 2 to 6         13,203  23.0 
 7 to 22         14,739  25.6 
 23 to 147         14,420  25.1 
Quartile of Urology Centers    
 0 to 3         14,107  24.5 
 4 to 16         14,390  25.0 
 17 to 44         14,130  24.6 
 45 to 343         14,862  25.9 
Year of Diagnosis   
 2002-2005         28,275  49.2 
 2006-2009         29,214  50.8 
Need Characteristics 
Number of Other Chronic Conditions   
 ≤  One         38,435  66.9 
 > One         19,054  33.1 
T-Stage   
 ≤T1         32,063  55.8 
 T2         23,905  41.6 
 ≥ T3           1,521  2.6 
 
 
Notes: Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 
2002 and 2009 and alive throughout the observation period. 
 
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; PCP: Primary Care Physician; 
RESP: Respiratory conditions; RP: Radical Prostatectomy; RT: Radiation Therapy
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Table 4. 2  
Number and Percentage with Non-Cancer Related Hospitalizations during the Pre- and Post-Cancer Period 
Elderly Medicare beneficiaries with Incident Prostate Cancer Surveillance, Epidemiology and End Results (SEER)-Medicare 
Linked Database-2002-2010 
     Pre-Cancer  Period  Post-Cancer Period 
    t1 t2 t3 t4 t5 t6 
  N % N % N % N % N % N % 
  Overall 2,202 3.8 1,967 3.4 2,244 3.9 5,297 9.2 2,835 4.9 2,875 5.0 
Types of Chronic Conditions***           
 None*** 367 1.4 357 1.4 477 1.8 1,493 5.8 528 2.0 553 2.1 
 CM only** 1,015 4.7 929 4.3 992 4.6 2,308 10.6 1,331 6.1 1,322 6.1 
 MH only** 26 3.2 23 2.8 35 4.3 63 7.7 33 4.1 33 4.1 
 RESP only** 74 3.4 55 2.4 60 2.6 192 8.4 80 3.5 74 3.2 
 CM + MH** 101 4.6 76 6.6 90 7.8 204 17.8 112 9.8 113 9.8 
 CM + RESP** 499 9.8 435 8.5 497 9.7 874 17.1 622 12.2 659 12.9 
 All Three*** 120 19.5 92 15.0 93 15.1 163 26.5 129 21.0 121 19.7 
              
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 and 2009 and alive throughout the observation period. 
Significant differences in non-cancer hospitalizations over time were tested with Wald chi-square, after accounting for correlations due to repeated measures. % represented 
in the column are column percentage.                
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental illness; Q1-Q6: Quarter1 -6; RESP: Respiratory conditions; 
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Table 4. 3 
Adjusted Odds Ratios and 95% Confidence Intervals (CI)  of 
Cancer Diagnosis Period From GEE models on Non-Cancer 
Related Hospitalizations Elderly Men with Incident Prostate 
Cancer Surveillance, Epidemiology and End Results (SEER)-
Medicare Linked Database-2000-2010 
Model 1, adjusting for pre- and post-cancer period 
  OR 95% CI Sig. 
Variable    
 Pre-cancer Ref   
 Post-cancer 1.77 [1.71,1.82] *** 
Model 2, adjusting for pre- and post-cancer period + Types of Chronic 
Conditions  
  AOR 95% CI Sig. 
 Pre-cancer Ref   
 
 
Post-cancer 1.79 [1.73,1.84] *** 
Model 3, adjusting for pre- and post-cancer period + Types of Chronic 
Conditions + predisposing, enabling, need, and external environment 
characteristics   
  AOR 95% CI Sig. 
 Pre-cancer Ref   
 Post-cancer 1.80 [1.75, 186] *** 
     
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 
and 2009 and alive throughout the observation period. Significant differences are based on the log-likelihood test 
using a repeated measure generalized estimating equations.  
 
AOR: Adjusted Odds Ratio; GEE: Generalized Estimating Equation;  OR: Odds Ratio; Sig: Level of Sig: 
Significance.  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05  
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Table 4. 4  
Predicted Probabilities with 95% Confidence Intervals for Types of Chronic Conditions From GEE analysis 
on Non-Cancer Related Hospitalizations Elderly Medicare Beneficiaries with Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database-2000-2010 
  Pre-cancer Post-cancer Changes in Additive 
  P 95% CI P 95% CI Probabilities Effect 
Model 1, adjusted for pre- and post-cancer period   
Overall*** 0.037 [0.036, 0.038] 0.064 [0.063, 0.065] 0.027  
       
Model 2, adjusted for pre- and post-cancer period + Types of Chronic Conditions 
Overall*** 0.031 [0.030,0.031] 0.055 [0.054, 0.056] 0.024  
Types of Chronic Conditions***     
 None 0.018 [0.017, 0.018] 0.031 [0.030, 0.032] 0.013 Ref 
 CM only 0.044 [0.043, 0.046] 0.077 [0.075, 0.079] 0.033 0.020 
 MH only 0.032 [0.027, 0.037] 0.055 [0.047, 0.063] 0.023 0.010 
 RESP only 0.029 [0.026, 0.031] 0.05 [0.045, 0.054] 0.021 0.008 
 CM + MH 0.075 [0.069, 0.081] 0.127 [0.117, 0.137] 0.052 0.039 
 CM + RESP 0.087 [0.084, 0.091] 0.146 [0.141, 0.151] 0.059 0.046 
 All Three 0.150 [0.138, 0.162] 0.239 [0.222, 0.256] 0.089 0.076 
        
Model 3 adjusted for pre- and post-cancer period + Types of Chronic Conditions + predisposing, enabling, need, 
and external environment characteristics   
Overall*** 0.028 [0.027, 0.029] 0.050 [0.049, 0.051] 0.022  
Types of Chronic Conditions***     
 None 0.017 [0.017, 0.018] 0.031 [0.030, 0.032] 0.014 Ref 
 CM only 0.039 [0.038, 0.041] 0.069 [0.067, 0.071] 0.030 0.016 
 MH only 0.027 [0.023, 0.031] 0.048 [0.041, 0.055] 0.021 0.007 
 RESP only 0.022 [0.020, 0.024] 0.039 [0.035, 0.043] 0.017 0.003 
 CM + MH 0.056 [0.051, 0.061] 0.097 [0.089, 0.105] 0.041 0.027 
 CM + RESP 0.063 [0.061, 0.065] 0.108 [0.103, 0.112] 0.045 0.031 
 All Three 0.103 [0.095, 0.115] 0.172 [0.159, 0.187] 0.069 0.055 
                
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 
and 2009 and alive throughout the observation period. Significant differences are based on the log-likelihood test 
using a repeated measure generalized estimating equations.  
    
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; RESP: Respiratory conditions; 
Sig: Level of Significance;  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
                                                                                                    


































Elderly Men diagnosed with prostate cancer as primary cancer at the 
age 67 years and above, malignant tumor, alive at the time of diagnosis 
and diagnosed during 2002 to 2009 with 36-month continuous 
eligibility in Medicare Part A and Part B and no HMO enrollment 
during entire 36-month of study period  
N = 57,489 
 
Reasons for exclusion: 
 Men with carcinoma in-situ (N =47) 
 Men diagnosed with prostate cancer at age 
66  or below or dead during study 
periods   
     (N =111,643) 
 
 
Men with prostate cancer identified using SEER site recode: 54 and 
ICD-10-Code: C61.9 
N =358,439 
Men diagnosed with prostate cancer as the primary cancer  
and alive at the time of diagnosis  
N = 289,701 
 
Reason for exclusion:  
 Men with other primary cancer (N=25,785) 
 Men diagnosed with prostate cancer at the 
time of death or autopsy (N= 2,944) 





Elderly men diagnosed with prostate cancer as the primary cancer at the 
age 67 years and above, malignant tumor, alive at the time of diagnosis 
and diagnosed from 2002 to 2009  
N = 178,011 
 
Reasons for exclusion: 
 No Part A and B enrollment (N =70,559) 
 
 
Elderly men diagnosed with prostate cancer as the primary cancer at the 
age 67 years and above, malignant tumor, alive at the time of diagnosis 
and diagnosed during 2002 to 2009 with 36-month continuous 
eligibility in Medicare Part A and Part B and no HMO enrollment 
during entire 36-month of study period   
N = 101,302 
 
Reasons for exclusion: 
 Incident chronic conditions a year 
preceding and proceeding prostate cancer 
diagnosis  (N = 43,813) 
 Missing information on race, education, 
urologist or radiation oncology unit in 




Appendix 4. 1 Study Cohort Development Chart for Study Population of Elderly Medicare Beneficiaries diagnosed with Prostate 
Cancer 
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Appendix 4. 2 Sensitivity Analysis: Non-cancer hospitalization definition 2-Number and Percentage with Non-Cancer Related 
Hospitalizations during the Pre- and Post-Cancer Period Elderly Medicare beneficiaries with Incident Prostate Cancer 
Surveillance, Epidemiology and End Results (SEER)-Medicare Linked Database-2002-2010 
     Pre-Cancer  Period  Post-Cancer Period 
    t1 t2 t3 t4 t5 t6 
  N % N % N % N % N % N % 
  Overall  2,080  3.6  1,848  3.2  2,109  3.7  2,905  5.1  2,572  4.5  2,664  4.6 
Types of Chronic Conditions***           
 None*** 332 1.3 326 1.3 433 1.7 660 2.6 437 1.7 488 1.9 
 CM only** 964 4.4 874 4.0 942 4.3 1,311 6.0 1,203 5.5 1,220 5.6 
 MH only** 24 3.0 21 2.6 34 4.2 29 3.6 30 3.7 30 3.7 
 RESP only** 71 3.1 49 2.2 58 2.5 96 4.2 72 3.2 68 3.0 
 CM + MH** 98 8.5 74 6.4 86 7.5 116 10.1 101 8.8 102 8.9 
 CM + RESP** 478 9.3 415 8.1 468 9.2 579 11.3 601 11.8 639 12.5 
 All Three*** 113 18.4 89 14.5 88 14.3 114 18.6 128 20.8 117 19.1 
              
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 
and 2009 and alive throughout the observation period. Significant differences in NCHs over time were tested with 
Wald chi-square, after accounting for correlations due to repeated measures. % represented in the column are 
column percentage.           
     
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental illness; RESP: Respiratory conditions; 
 





                                                                                                    





Appendix 4. 3 Sensitivity Analysis: Non-cancer hospitalization 
definition 2-Adjusted Odds Ratios and 95% Confidence Intervals 
(CI) of Cancer Diagnosis Period  From GEE models on Non-Cancer 
Related Hospitalizations Elderly Men with Incident Prostate 
Cancer Surveillance, Epidemiology and End Results (SEER)-
Medicare Linked Database-2000-2010 
Model 1, adjusting for pre- and post-cancer period 
  OR 95% CI Sig. 
Variable    
 Pre-cancer Ref   
 Post-cancer 1.37 [1.32,1.41] *** 
Model 2, adjusting for pre- and post-cancer period + Types of Chronic 
Conditions  
  AOR 95% CI Sig. 
 Pre-cancer Ref   
 
 
Post-cancer 1.38 [1.33,1.42] *** 
Model 3, adjusting for pre- and post-cancer period + Types of Chronic 
Conditions + predisposing, enabling, need, and external environment 
characteristics   
  AOR 95% CI Sig. 
 Pre-cancer Ref   
 Post-cancer 1.38 [1.33, 1.43] *** 
     
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 
and 2009 and alive throughout the observation period. Significant differences are based on the log-likelihood test 
using a repeated measure generalized estimating equations.  
 
AOR: Adjusted Odds Ratio; GEE: Generalized Estimating Equation; AOR: Adjusted Odds Ratio; Sig: Level of Sig: 
Significance.  
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05  
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 Appendix 4. 4 Sensitivity Analysis: Non-cancer hospitalization definition 2-Predicted Probabilities with 95% 
Confidence Intervals for Types of Chronic Conditions From GEE analysis on Non-Cancer Related 
Hospitalizations Elderly Medicare Beneficiaries with Incident Prostate Cancer Surveillance, Epidemiology 
and End Results (SEER)-Medicare Linked Database-2000-2010 
  Pre-cancer Post-cancer Changes in Additive 
  P 95% CI P 95% CI Probabilities Effect 
Model 1, adjusted for pre- and post-cancer period   
Overall*** 0.035 [0.034, 0.036] 0.047 [0.046, 0.048] 0.012  
       
Model 2, adjusted for pre- and post-cancer period + Types of Chronic Conditions 
Overall*** 0.028 [0.027,0.029] 0.038 [0.037, 0.039] 0.010  
Types of Chronic Conditions***     
 None 0.018 [0.017, 0.018] 0.031 [0.030, 0.032] 0.013 Ref 
 CM only 0.044 [0.043, 0.046] 0.077 [0.075, 0.079] 0.033 0.020 
 MH only 0.032 [0.027, 0.037] 0.055 [0.047, 0.063] 0.023 0.010 
 RESP only 0.029 [0.026, 0.031] 0.05 [0.045, 0.054] 0.021 0.008 
 CM + MH 0.075 [0.069, 0.081] 0.127 [0.117, 0.137] 0.052 0.039 
 CM + RESP 0.087 [0.084, 0.091] 0.146 [0.141, 0.151] 0.059 0.046 
 All Three 0.150 [0.138, 0.162] 0.239 [0.222, 0.256] 0.089 0.076 
        
Model 3 adjusted for pre- and post-cancer period + Types of Chronic Conditions + predisposing, enabling, need, 
and external environment characteristics   
Overall*** 0.027 [0.026, 0.028] 0.036 [0.036, 0.038] 0.009  
Types of Chronic Conditions***     
 None 0.016 [0.015, 0.016] 0.021 [0.020, 0.022] 0.008 Ref 
 CM only 0.039 [0.038, 0.041] 0.053 [0.052, 0.055] 0.014 0.008 
 MH only 0.026 [0.022, 0.030] 0.036 [0.030, 0.041] 0.010 0.004 
 RESP only 0.021 [0.019, 0.023] 0.029 [0.026, 0.032] 0.008 0.002 
 CM + MH 0.056 [0.051, 0.061] 0.075 [0.069, 0.082] 0.020 0.014 
 CM + RESP 0.066 [0.062, 0.069] 0.088 [0.084, 0.092] 0.023 0.017 
 All Three 0.107 [0.097, 0.116] 0.141 [0.129, 0.153] 0.035 0.029 
                
 
Notes: Based on 57,489 elderly men, aged 67 years and older, diagnosed with incident prostate cancer between 2002 
and 2009 and alive throughout the observation period. Significant differences are based on the log-likelihood test 
using a repeated measure generalized estimating equations.  
    
Abbreviations: CM: Cardio-metabolic conditions; MH: Mental health conditions; RESP: Respiratory conditions; Sig: 
Level of Significance;  
 
*** p < .001; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Chapter 5 
Discussion of Findings and Research Implications 
5.1 SUMMARY OF FINDINGS & DISCUSSION   
With an increase in the cancer-related survival and risk of non-cancer mortality among elderly men 
with prostate cancer, the Office of Cancer Survivorship (OCS) and Institute of Medicine (IOM) have 
prioritized the co-management of chronic conditions and cancer. The current study, which focuses on the 
role of chronic conditions in cancer treatment, cancer and non-cancer outcomes, is timely, unique and in 
alignment with the scope of the OCS and IOM.  In the current study, one in two elderly (> 67 years) fee-
for-service Medicare beneficiaries with incident prostate cancer had a pre-existing chronic condition, 
consistent with the published studies. Among those with pre-existing chronic conditions, the cardio-
metabolic conditions were highly prevalent (53.8%).  These findings suggest that elderly men with prostate 
cancer have a significant illness burden.    
In the current study, types of pre-existing chronic conditions were not associated with cancer stage 
at diagnosis. One in 10 elderly Medicare beneficiaries had advanced prostate cancer at diagnosis.  Elderly 
men with none of three types of chronic conditions were more likely to be diagnosed with advanced 
prostate cancer as compared to those with all the three types of chronic conditions. No statistically 
significant associations between other types of chronic conditions and the risk of advanced stage prostate 
cancer were observed.  These findings suggest that the strategies for reducing the risk of advanced prostate 
cancer at diagnosis should focus on elderly men with none of three common types of chronic conditions. 
 The initial prostate cancer treatment rates were high even among elderly men with incident 
localized prostate cancer. In the study cohort, three in four elderly Medicare beneficiaries diagnosed with 
incident localized prostate cancer received either RP, RT or hormone therapy during the first six-month 
after cancer diagnosis. Although there is no evidence that the initial cancer treatment can be beneficial the 
in long-term for elderly men with prostate cancer and pre-existing chronic conditions, many received 
treatment, suggesting an overuse of RP and RT among elderly men with localized incident prostate cancer.  
The types of chronic conditions were associated with some types of the initial cancer treatment. As 
compared to elderly men with all the three types of chronic conditions, those with none of three types of 
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chronic conditions were more likely to receive RP/RT, men in all other chronic condition categories 
(except “mental health and respiratory conditions” and “only mental health conditions”) were more likely 
to receive RT.  There were no differences in the receipt of hormone therapy by the types of chronic 
conditions. Again, prior research has shown that elderly men with cardio-metabolic conditions may not 
benefit from cancer treatment as these men are at high risk for non-cancer related mortality (8, 50).  These 
findings reinforce the need for specific clinical guidelines for the treatment of cancer in presence of 
particular types of chronic conditions.   
The types of chronic conditions were associated with bowel, sexual and urinary dysfunction. As 
compared to those with all the three types of conditions, elderly men with none of the three types of 
chronic conditions or only respiratory conditions or only cardio-metabolic were less likely to have bowel 
and urinary dysfunctions. Whereas, as compared to elderly men with all the three types of conditions, those 
with none of the three types of chronic conditions, and only respiratory conditions were more likely to have 
sexual dysfunctions. The reasons for why these particular combinations are associated with lower risk of 
bowel and urinary dysfunctions were not known.  Future research needs to explore the possible 
pathophysiological link between types of chronic conditions and bowel and urinary dysfunction.  
 The treatment of pre-existing T2DM with metformin during the year before the incident prostate 
cancer diagnosis reduced the risk for advanced prostate cancer at diagnosis. Among elderly men with 
prostate cancer and T2DM, metformin use during the year before diagnosis of incident prostate cancer was 
associated with a statistically significant reduction in the risk of advanced prostate cancer at diagnosis, 
after controlling for the observed selection bias between metformin users and non-users and other 
independent variables. This finding is consistent with the pre-clinical evidence.  If the findings are 
replicated by other observational studies and RCTs, metformin can be used as a preventive therapy for 
reducing the risk of advanced prostate cancer.  
Metformin users were more likely to receive RP as the initial cancer treatment as compared to 
non-users.   The reasons for a higher rate of RP among metformin users are not clear.  Future research 
needs to explore the reasons as to why metformin users were more likely to receive aggressive treatments.    
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Prostate cancer diagnosis was associated with an increased risk of non-cancer hospitalizations 
among elderly men with incident prostate cancer.  Elderly Medicare beneficiaries with incident prostate 
cancer had higher rates of non-cancer hospitalizations during the post-cancer period as compared to the 
pre-cancer period, even after controlling for a comprehensive list of risk factors. The highest rates of non-
cancer hospitalizations were observed during first four months after the diagnosis of prostate cancer.  
Collectively, these findings suggest the need for further research on the relationship between the 
appropriate management of pre-existing chronic conditions during the pre-cancer period and the risk of 
non-cancer hospitalizations during the post-cancer period.  Along with cancer care, better surveillance 
efforts and closer monitoring of chronic conditions may be needed, especially at the time of incident 
cancer diagnosis among elderly men, to reduce the risk of excess non-cancer hospitalizations. 
The magnitude of the relationship between the diagnosis of prostate cancer and non-cancer 
hospitalizations varied by the types of pre-existing chronic conditions. Those with all the three types of 
conditions, both cardio-metabolic conditions and respiratory conditions, and both cardio-metabolic and 
mental-health conditions had a greater increase in the risk of non-cancer-hospitalizations (between the pre-
cancer and post-cancer period) as compared to those with none of the three types of chronic conditions. 
The study also has a key methodological implication for estimating cancer-related healthcare utilization. 
Typically, cancer-related annual healthcare utilizations among men with prostate cancer are estimated by 
subtracting the total healthcare utilization in a year before cancer diagnosis from the total utilization after 
in a year after cancer diagnosis (5-9).  Such method of estimating cancer-related healthcare utilizations 
may overestimate prostate-cancer-related utilizations as elderly men with incident prostate cancer had 
higher rates of non-cancer hospitalizations during post-cancer as compared to pre-cancer period.  
5.2 IMPLICATIONS FOR FUTURE RESEARCH  
Historically, the role of chronic conditions in cancer has been examined using comorbidity indices 
or the number of chronic conditions. The current study is the first of its kind to provide comprehensive 
information on the role of specific types of chronic conditions and their combinations in prostate cancer 
diagnosis, treatment, and cancer and non-cancer outcomes. The study findings provide some actionable 
evidence that can be utilized in real-world treatment decisions. One of the major research implications is to 
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conduct future studies among individuals with other types of cancers with better survival profile such as 
the localized breast, colon, rectum, melanoma, testis, thyroid, urinary bladder and uterine corpus cancers.   
In the current study it was observed that elderly men without the commonly prevalent chronic 
conditions had advanced prostate cancer at diagnosis.  Future research studies should examine the impact 
of less common conditions such as inflammatory related conditions, smoking associated disorders, sexually 
transmitted disease on prostate cancer risk, as these conditions also share common risk factors for 
developing prostate cancer. 
The current study found a reduced risk of advanced prostate cancer diagnosis with metformin use 
among elderly men with T2DM and prostate cancer.   Well-designed pragmatic trials are needed to provide 
evidence on the effectiveness of metformin use.   
The SEER authority advised against the use of the prostate specific antigen (PSA) as the PSA 
levels were not accurately recorded over the years.  In the current study, PSA levels could not be 
incorporated to examine cancer stage at diagnosis. Therefore, future research should focus on the reliability 
and validity of using the PSA levels from the real-world electronic medical records.  
As the elderly men with prostate cancer at higher risk for non-cancer hospitalizations during the 
post-cancer period as compared to the pre-cancer period, future studies should examine the reasons behind 
the increased risk.  
5.3 STUDY LIMITATIONS 
The current study has some limitations. First, the study cohort was restricted to elderly men 
enrolled in fee-for-service Medicare services only residing in the SEER-regions, therefore, study findings 
cannot be generalized to younger men, enrolled in managed care plans or commercial plans, and those 
residing in non-SEER regions. In addition, in the second aim, our study restricted to elderly men with a 
history of diabetes, the findings cannot be generalized to those with incidence of prostate cancer and no 
prior history of diabetes. The clinical severity of the chronic conditions could not be measured. 
Furthermore, the current study utilized the registry-linked administrative claims data which have either no 
information or limited validity of codes to identify body-mass index, exercise, and smoking status, which 
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may be associated severity, advanced prostate cancer at diagnosis, the initial treatment receipt and clinical 
outcome among elderly men with prostate cancer.  In addition, the types of chronic conditions were 
considered as incurable conditions. The cardio-metabolic conditions and respiratory conditions can be 
considered as incurable conditions, however, the mental-health conditions such as depression can be cured 
with proper medications and other clinical approaches.  Therefore, the chronic condition classification 
might overestimate the presence of such conditions. Given this limitation, the presence of each of those 
conditions was identified in the immediate periods before diagnosis of cancer.  
Despite these limitations, the current study contributed to the nascent literature on the role of 
selected chronic conditions and their combinations on the stage of cancer, the initial cancer treatment, 
cancer- and non-cancer outcomes among elderly men with incident prostate cancer using the largest 
population-based cancer registries-Medicare-linked database of the US.  
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